Synthesis and Characterization of Caffeic Acid and Dihydrocaffeic Acid Derivatives as Antifungal Agents

by

Yuxi Chen

A thesis submitted to the School of Graduate Studies in partial fulfillment of the requirements for the degree of Master of Science

School of Pharmacy
Memorial University of Newfoundland
Abstract

Invasive fungal infection, a major cause of morbidity and mortality in immuno-compromised hosts, is of importance and is significantly increasing in incidence in recent years. Although there are a number of antifungal agents currently available, they are associated with various limitations. Being inhibitors of fungal cell wall biosynthesis, the class of echinocandins is characterized by outstanding safety profiles and great potential in combination antifungal therapy, but they fall short in oral bioavailability. A discovery of peptidomimetic analogues of echinocandin B, with potential inhibitory activity against 1,3-β-D-glucan synthase (an enzyme essential for the biosynthesis of fungal cell walls), was initiated by our research group. A series of structurally related derivatives (chlorogenic, quinic, caffeic and dihydrocaffeic acid derivatives) were later designed to mimic the backbone of echinocandins.

Further studies have been carried out on optimization of synthesis and modifications of a caffeic acid derivative. Due to the instability problems of previously reported compounds, a new molecule, a dihydrocaffeic acid derivative, has been designed and synthesized. It was found that adopting a few optimized procedures can not only improve the yield and purity of the caffeic acid derivatives, but also save a lot of time in synthesis.
Acknowledgments

Foremost, I would like to express my sincere gratitude to the late Dr. Mohsen Daneshtalab, who was my supervisor when I started my MSc program. I feel very grateful to have had him in my life for all the support and guidance he gave to me, and all the time we spent together in the lab. The promise I made to him drove me to overcome difficulties in finishing my thesis. I will always miss him and cherish the memory.

I would never have been able to finish dissertation without the help and guidance of my supervisor Dr. Lili Wang and my committee member Dr. Sunil V. Pansare. I would like to offer my deepest gratitude to Dr. Lili Wang for giving me all the help when I needed them the most and also for her continuous caring and patience. I would like to thank Dr. Sunil Pansare, who patiently answered every question I had and kindly offered me so many valuable advices. I also feel so blessed of my friendship with many students and colleagues during my graduate study. I gratefully acknowledge the support from School of Graduate Studies at Memorial University and the A. G. Hatcher Memorial Scholarship.

Most of all, I would like to thank my parents for their non-stop love and support through all these years. I would also like to thank my husband, Runlin Shi, for his love, understanding and encouragement. He was always there for me when I felt lost and stood by me through ups and downs.
# Table of Contents

Abstract ........................................................................................................................................ i
Acknowledgments ......................................................................................................................... ii
Table of Contents ........................................................................................................................... iii
List of Tables .................................................................................................................................. v
List of Figures ................................................................................................................................... vi
List of Schemes ............................................................................................................................... vii
List of Abbreviations ...................................................................................................................... viii

Chapter 1. Introduction ................................................................................................................... 1
  1.1 Fungi and fungal infections ................................................................................................. 1
      1.1.1 Fungi .......................................................................................................................... 1
      1.1.2 Fungal infections ....................................................................................................... 2
  1.2 Diagnostic methods for fungal infections ........................................................................... 9
      1.2.1 GM antigen test .......................................................................................................... 11
      1.2.2 BDG detection assay ................................................................................................. 14
      1.2.3 Polymerase chain reaction (PCR) assay .................................................................. 21
  1.3 Antifungal agents .................................................................................................................. 25
      1.3.1 Polyenes .................................................................................................................... 26
      1.3.2 Azoles ....................................................................................................................... 28
      1.3.3 Echinocandins .......................................................................................................... 39
  1.4 Antifungal strategies ............................................................................................................. 52
      1.4.1 Antifungal prophylaxis .............................................................................................. 52
      1.4.2 EAT ............................................................................................................................ 55
      1.4.3 Preemptive therapy ................................................................................................... 59
      1.4.4 Targeted therapy ....................................................................................................... 62
      1.4.5 Combination therapy ............................................................................................... 64
  1.5 Rationale of the project ......................................................................................................... 66

Chapter 2. Objectives .................................................................................................................... 84
Chapter 3. Materials and Methods ............................................. 86

3.1 Materials ........................................................................... 86

3.2 Chemical synthesis .............................................................. 89

3.2.1 Synthesis of 3,4-diacetoxycinnamoyl chloride 15a .......... 89

3.2.2 Synthesis of H$_2$N-Orn(Boc)-octyloxyaniline 13a ........ 90

3.2.3 Synthesis of caffeic acid derivative 16g ...................... 92

3.2.4 Synthesis of 3,4-diacetoxydihydro-caffeoyl chloride 19b .... 94

3.2.5 Synthesis of dihydrocaffeic acid derivative 20c .......... 94

Chapter 4. Results and Discussion ............................................. 96

4.1 Synthesis of 3,4-diacetoxycinnamoyl chloride 15a .......... 96

4.2 Synthesis of H$_2$N-Orn(Boc)-octyloxyaniline 13a ........ 98

4.3 Synthesis of caffeic acid derivative 16g ...................... 100

4.4 Synthesis of 3,4-diacetoxydihydro-caffeoyl chloride 19b .... 103

4.5 Synthesis of dihydrocaffeic acid derivative 20c .......... 104

Chapter 5. Experimental Procedures and Characterization .......... 108

5.1 Synthesis of 3,4-diacetoxycinnamoyl chloride 15a .......... 108

5.2 Synthesis of H$_2$N-Orn(Boc)-octyloxyaniline 13a ........ 109

5.3 Synthesis of caffeic acid derivative 16g ...................... 111

5.4 Synthesis of 3,4-diacetoxydihydro-caffeoyl chloride 19b .... 114

5.5 Synthesis of dihydrocaffeic acid derivative 20c .......... 115

References .................................................................................. 119

Appendices .................................................................................. A-1
List of Tables

Table 1.1. Strategies for management of IFIs .......................... 53
Table 1.2. BDG synthase inhibitory and antifungal activities .......... 79
List of Figures

Figure 1.1. Fungal reproduction ................................................. 2
Figure 1.2. Morphogenesis in different fungal species .................... 5
Figure 1.3. Risk factors for developing IFI ................................. 8
Figure 1.4. Structure of amphotericin B (AmB), 1 ......................... 27
Figure 1.5. Structures of Fluconazole 2, Voriconazole 3 and
Posaconazole 4 ............................................................... 31
Figure 1.6. Structures of echinocandin B 5 and aculeacin A 6 .......... 41
Figure 1.7. Structures of Caspofungin 7, Micafungin 8 and
Anidulafungin 9 ............................................................... 43
Figure 1.8. Structures of echinocandin B 5, pneumocandin A0 5a, B0 5b,
C0 5c, and cilofungin 5d .................................................. 68
Figure 1.9. Structures of echinocandin B 5, CGA 10 and its derivatives
11 and 12l .................................................................. 71
Figure 1.10. Overlap of CGA derivatives 11, 12l with echinocandin B 5
..................................................................................... 74
Figure 1.11. (a) Structure of the different sections in CGA derivative 12l
(b) Hydrolysis of CGA derivative 12l ................................. 75
Figure 1.12. Comparison of CGA derivative 12l with caffeic acid
derivative 16g ................................................................. 77
Figure 1.13. Resonance structures of amide bond (with and without
double bond) ............................................................... 82
Figure 2.1. Structures of caffeic acid derivative 16g and dihydrocaffeic
acid derivative 20c .......................................................... 85
Figure 3.1. Structure of 2-(((9H-fluoren-9-yl)methoxy)carboyl)amino)5((tert-butoxycarbonyl)amino)pentanoic acid (Fmoc-Orn-
(Boc)-OH) 17 ........................................................... 90
Figure 3.2. Structure of CMC .................................................. 91
List of Schemes

Scheme 1.1. Synthesis of CGA derivatives 12a-l ..........................73
Scheme 1.2. Synthesis of quinic acid derivatives 14a-e ................. 76
Scheme 1.3. Synthesis of caffeic acid derivatives 16a-i .................... 78
Scheme 1.4. The deduced metabolic scheme for CGA derivative 12l, quinic acid derivative 14b, and caffeic acid derivative 16g, in rats. ................................................................. 83
Scheme 3.1. Synthesis of 3,4-diacetoxyccinnamoyl chloride 15a ...... 90
Scheme 3.2. Synthesis of H$_2$N-Orn(Boc)-octyloxyaniline 13a ........ 91
Scheme 3.3. Synthesis of caffeic acid derivative 16g ....................... 92
Scheme 3.4. Mechanism of Boc deprotection ................................. 93
Scheme 3.5. Synthesis of 3,4-diacetoxydihydro-caffeoyl chloride 19b . 94
Scheme 3.6. Synthesis of dihydrocaffeic acid derivative 20c .......... 95
Scheme 4.1. Mechanism of acyl chloride formation with oxalyl chloride ................................................................. 97
Scheme 4.2. Preparation of Fmoc-Orn(Boc)-octyloxyaniline 13d with the previously reported method and newly developed technique ................................................................. 99
Scheme 4.3. Mechanism for the base catalyzed hydrolysis of acetoxy group ................................................................. 101
### List of Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ac₂O</td>
<td>Acetic anhydride</td>
</tr>
<tr>
<td>ACS</td>
<td>American Chemical Society</td>
</tr>
<tr>
<td>AmB</td>
<td>Amphotericin B</td>
</tr>
<tr>
<td>AUC-SROC</td>
<td>Area under the curve summary receiver operating characteristic</td>
</tr>
<tr>
<td>BAL</td>
<td>Bronchoalveolar lavage</td>
</tr>
<tr>
<td>BDG</td>
<td>1,3-β-D-glucan</td>
</tr>
<tr>
<td>Boc</td>
<td>Butyloxy carbonyl</td>
</tr>
<tr>
<td>Bp</td>
<td>Boiling point</td>
</tr>
<tr>
<td>C. albicans</td>
<td>Candida albicans</td>
</tr>
<tr>
<td>CaCl₂</td>
<td>Calcium chloride</td>
</tr>
<tr>
<td>CDCl₃</td>
<td>Deuterated chloroform (Chloroform-(d))</td>
</tr>
<tr>
<td>cDNA</td>
<td>Complementary deoxyribonucleic acid</td>
</tr>
<tr>
<td>CD₃OD</td>
<td>Deuterated methanol (Methanol-(d₄))</td>
</tr>
<tr>
<td>CDR</td>
<td>Candida drug resistance</td>
</tr>
<tr>
<td>CGA</td>
<td>Chlorogenic acid</td>
</tr>
<tr>
<td>CH₂Cl₂</td>
<td>Dichloromethane</td>
</tr>
<tr>
<td>CMC</td>
<td>1-Cyclohexyl-3-(2-morpholinoethyl) carbodiimidemetho-p-toluenesulfonate</td>
</tr>
<tr>
<td>(COCl)₂</td>
<td>Oxalyl chloride</td>
</tr>
<tr>
<td>Acronym</td>
<td>Definition</td>
</tr>
<tr>
<td>---------</td>
<td>------------------------------------------------</td>
</tr>
<tr>
<td>CO</td>
<td>Carbon monoxide</td>
</tr>
<tr>
<td>CO₂</td>
<td>Carbon dioxide</td>
</tr>
<tr>
<td>CSF</td>
<td>Cerebrospinal fluid</td>
</tr>
<tr>
<td>CT</td>
<td>Computed tomography</td>
</tr>
<tr>
<td>DMAP</td>
<td>4-Dimethylamino pyridine</td>
</tr>
<tr>
<td>DMF</td>
<td>N,N-Dimethylformamide</td>
</tr>
<tr>
<td>DNA</td>
<td>Deoxyribonucleic acid</td>
</tr>
<tr>
<td>DOR</td>
<td>Diagnostic odd ratio</td>
</tr>
<tr>
<td>EAT</td>
<td>Empirical antifungal treatment</td>
</tr>
<tr>
<td>ECIL</td>
<td>European Conference of Infections in Leukaemia</td>
</tr>
<tr>
<td>EIA</td>
<td>Enzyme immunoassay</td>
</tr>
<tr>
<td>ELISA</td>
<td>Enzyme-linked immunosorbent assay</td>
</tr>
<tr>
<td>EORTC/MSG</td>
<td>The European Organization for Research and</td>
</tr>
<tr>
<td></td>
<td>Treatment of Cancer / Mycoses Study Group</td>
</tr>
<tr>
<td>ESI</td>
<td>Electrospray</td>
</tr>
<tr>
<td>FDA</td>
<td>Food and Drug Administration</td>
</tr>
<tr>
<td>Fmoc</td>
<td>Fluorenylmethyloxycarbonyl</td>
</tr>
<tr>
<td>GC</td>
<td>Gas chromatography</td>
</tr>
<tr>
<td>GM</td>
<td>Galactomannan</td>
</tr>
<tr>
<td>¹H NMR</td>
<td>Proton nuclear magnetic resonance</td>
</tr>
<tr>
<td>HCl</td>
<td>Hydrogen chloride</td>
</tr>
<tr>
<td>HOBT</td>
<td>Hydroxybenzotriazole</td>
</tr>
<tr>
<td>Acronym</td>
<td>Description</td>
</tr>
<tr>
<td>---------</td>
<td>-------------</td>
</tr>
<tr>
<td>HPLC</td>
<td>High-performance liquid chromatography</td>
</tr>
<tr>
<td>HRCT</td>
<td>High resolution computed tomography</td>
</tr>
<tr>
<td>HSC</td>
<td>Hematopoietic stem cell</td>
</tr>
<tr>
<td>HSCT</td>
<td>Hematopoietic stem cell transplantation</td>
</tr>
<tr>
<td>IA</td>
<td>Invasive aspergillosis</td>
</tr>
<tr>
<td>IC</td>
<td>Invasive candidiasis</td>
</tr>
<tr>
<td>IC₅₀</td>
<td>Inhibitory concentration 50%</td>
</tr>
<tr>
<td>ICU</td>
<td>Intensive care unit</td>
</tr>
<tr>
<td>IDSA</td>
<td>Infectious Disease Society of America</td>
</tr>
<tr>
<td>IFI</td>
<td>Invasive fungal infection</td>
</tr>
<tr>
<td>IR</td>
<td>Infrared</td>
</tr>
<tr>
<td>ITS</td>
<td>Internally transcribed spacer</td>
</tr>
<tr>
<td>KOH</td>
<td>Potassium hydroxide</td>
</tr>
<tr>
<td>L-AmB</td>
<td>Liposomal amphotericin B</td>
</tr>
<tr>
<td>LC-MS</td>
<td>Liquid chromatography-mass spectrometry</td>
</tr>
<tr>
<td>MDR</td>
<td>Multidrug resistance</td>
</tr>
<tr>
<td>Na₂SO₄</td>
<td>Sodium sulfate</td>
</tr>
<tr>
<td>NaCl</td>
<td>Sodium chloride</td>
</tr>
<tr>
<td>NaHCO₃</td>
<td>Sodium bicarbonate</td>
</tr>
<tr>
<td>NHEt₂</td>
<td>Diethylamine</td>
</tr>
<tr>
<td>NMR</td>
<td>Nuclear magnetic resonance</td>
</tr>
<tr>
<td>OD</td>
<td>Optical density</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>ODS</td>
<td>Octadecyl-functionalized silica</td>
</tr>
<tr>
<td>OH⁻</td>
<td>Hydroxide anion</td>
</tr>
<tr>
<td>PCR</td>
<td>Polymerase chain reaction</td>
</tr>
<tr>
<td>PT</td>
<td>Piperacillin-tazobactam</td>
</tr>
<tr>
<td>RCT</td>
<td>Randomized controlled trial</td>
</tr>
<tr>
<td>RNA</td>
<td>Ribonucleic acid</td>
</tr>
<tr>
<td>rRNA</td>
<td>Ribosomal ribonucleic acid</td>
</tr>
<tr>
<td>SBECSD</td>
<td>Sulfobutyl ether β-cyclodextrin sodium</td>
</tr>
<tr>
<td>SOT</td>
<td>Solid organ transplant</td>
</tr>
<tr>
<td>TFA</td>
<td>Trifluoroacetic acid</td>
</tr>
<tr>
<td>THF</td>
<td>Tetrahydrofuran</td>
</tr>
<tr>
<td>TLC</td>
<td>Thin layer chromatography</td>
</tr>
<tr>
<td>TMS</td>
<td>Tetramethylsilane</td>
</tr>
<tr>
<td>UDP</td>
<td>Uridine diphosphate</td>
</tr>
<tr>
<td>UGT</td>
<td>Uridine diphosphate-glucuronosyltransferase</td>
</tr>
<tr>
<td>UPLC-APCI-MS/MS</td>
<td>Ultra-performance liquid chromatography-atmospheric-pressure chemical ionization-tandem mass spectrometry</td>
</tr>
<tr>
<td>UV</td>
<td>Ultraviolet</td>
</tr>
</tbody>
</table>
Chapter 1. Introduction

1.1 Fungi and fungal infections

1.1.1 Fungi

Fungi are actually primitive plants on Earth and can be found in air, in soil, on plants, and in water.\(^1\) Although there is still no body fossil evidence for the earliest organisms like fungi, biologists believe that fungi are an ancient group that must have evolved relatively early in geologic time, perhaps more than 1.5 billion years ago.\(^2\) They are a large group of eukaryotic organisms including microorganisms such as mushrooms, yeast, mold, and mildew. Despite their completely different appearance, fungi share many features in common with human beings, which creates a unique opportunity for them to cause severe infections. Eukaryotic cells, membrane-bound organelles and a nucleus, are key components for both humans and fungi.\(^3\) Due to their similarity to humans, certain opportunistic fungi can cause severe fungal infections that are characterized by high morbidity and mortality. Moreover, cell walls of fungi, as major components of these organisms, are different from plants, protists and bacteria. Instead of cellulose, which constitutes the cell walls of plants and some protists, chitin is the critical element of the cell walls of fungal cells.
1.1.2 Fungal infections

Among pathogenic microbes, eukaryotic pathogens, which include fungi and parasites, are receiving more and more attention from all over the world. This is due to the fact that drug resistance has been clinically observed more often than before, and fewer drugs or vaccines are available, compared to antibacterials and antivirals. Fungal infections of animals, including humans, are known as mycoses, with many different environmental and physiological factors contributing to the development of fungal diseases. Some fungi reproduce by spreading microscopic spores (Figure 1.1). These spores are often present in the air, where they can be inhaled or come into contact with the surfaces of the body, primarily the skin. As a result, fungal infections usually begin in the lungs or on the skin.

![Figure 1.1. Fungal reproduction](image)

Figure 1.1. Fungal reproduction
External factors, mainly environmental conditions, can trigger genetically-determined developmental states that lead to the emergence of specialized structures for sexual or asexual reproduction. As a critical element in fungal reproduction, the specialized structures are able to disperse spores or spore-containing propagules to facilitate the process. Different species of fungi have their own characteristics in reproduction. By comparing yeasts with molds, yeasts grow as solitary cells, while molds grow in the form of multicellular filaments called hyphae. As for reproduction, yeasts usually reproduce asexually through mitosis, also known as budding. On the other hand, molds are characterized by the development of hyphae through dispersing small spores, which can be either sexual or asexual (Figure 1.1). However, it is common that many fungi reproduce by using more than one method of propagation. In addition to budding yeast cells, yeasts such as Candida albicans (C. albicans) may also form pseudohyphae or even true hyphae as well.

Yet, of the wide variety of spores that land on the skin or are inhaled into the lungs, most do not cause infection, i.e., not all species of fungi would cause disease in human. Many different kinds of fungi live inside the human body in a benign equilibrium with it. When the body's immune system is weakened due to an illness or treatment such as with patients who have had hematopoietic stem cell (HSC) and solid organ transplants (SOT) or chemotherapy, the balance can be disturbed, allowing fungi to
overgrow causing disease.\textsuperscript{[6]} In fact, many fungi that cause mycoses may be part of the normal body flora (e.g., \textit{Candida}), and opportunists (e.g., \textit{Aspergillus}), existing in the environment, infect mainly immunocompromised people. Moreover, dimorphic organisms that are spore-forming molds in nature are able to convert into yeasts after entry into the human body, often by inhalation (e.g., \textit{Histoplasma}).\textsuperscript{[7]} It is noteworthy that dimorphic fungi can cause infections even in immunocompetent people. Statistically, the most frequent aetiological fungi are \textit{C. albicans}, \textit{Cryptococcus neoformans} and \textit{Aspergillus fumigatus}. The estimated annual incidence of invasive mycoses due to these pathogens is 72-228 infections per million population for \textit{Candida} species, 30-66 infections per million population for \textit{Cryptococcus neoformans}, and 12-34 infections per million population for \textit{Aspergillus} species.\textsuperscript{[8,9,10,11]}

Symptoms of fungal infections vary depending on the area of the body infected, which normally includes eyes, nails, skin, mouth, lung, genitals, and digestive tract. When the infection happens on the skin, itch, red rash, scaling and flaking of the skin are general symptoms. The most common symptom of onychomycose is the nail becoming thickened, discolored and maybe even bulged out or separated from the finger or toe completely. In addition, fungal infections in the lung and systemic fungal infections are characterized by cough, loss of appetite, and persistent fever of unknown cause.
As mentioned earlier, fungi do not always mean pathogenicity, since there are other factors contributing to actual fungal infections. With dimorphic fungi and some other fungal species, the transformation in growing forms plays a key role in the development of fungal infections. Due to thermotolerance, dimorphic fungi have the ability to grow at 37°C by transforming from filamentous moulds to unicellular yeasts in the host. Some opportunistic fungi can also grow in different forms depending on the infection sites, which has shown the flexibility in morphogenesis and metabolism of fungi (Figure 1.2). [12] This may have been the result of fungi evolvement in order to adapt to various environments.

Figure 1.2. Morphogenesis in different fungal species, adapted from Romani L. [12]
However, in recent years, patient characteristics, antifungal prophylaxis, and other factors appear to have contributed to a change in the spectrum of invasive fungal pathogens. [13] Non-\textit{albicans Candida}, \textit{Non-fumigatus Aspergillus}, and molds other than \textit{Aspergillus} have become more common pathogens causing invasive fungal infections (IFI). Many of these fungi were previously thought to be nonpathogenic and are now recognized as causes of invasive mycoses in immunocompromised patients. And most of these emerging fungi are resistant to or less susceptible than others to standard antifungal treatments, which makes the invasive infections caused by these previously rare fungi more difficult to diagnose and treat.

IFI is a fungal infection that can occur when fungi enter the bloodstream. For example, when \textit{Candida} yeasts enter the bloodstream, it can cause invasive candidiasis (IC). IFI, as a major cause of morbidity and mortality in immunocompromised hosts, is of importance and has significantly increased in incidence in recent years. [14] A few reasons have been proposed for the increase in IFIs, including the use of antineoplastic and immunosuppressive agents, broad-spectrum antibiotics, and prosthetic devices and grafts, and more aggressive surgery. [15] The rate of sepsis due to fungal organisms in the United States alone increased by 207\% during the period from 1979 through 2000. [16] In order to have efficient management of established IFI, the critical step is assessing the
clinical situation carefully and evaluating the risk factors that might have contributed to its emergence. Based on the current situation, some approaches have been developed to manage these infections, including prevention, antifungal prophylaxis, and empirical antifungal treatment (EAT). Lately, due to the recognition of risk factors that contribute to the development of IFIs, a few alternative management strategies, such as preemptive therapy and targeted prophylaxis, have been proposed to protect those patients who are at a very high risk. The main aim of management strategies is to prevent, or promptly treat, patients at risk. However, the management of IFIs currently has two major challenges: (1) In addition to difficulties in treatment, IFIs are also difficult to diagnose. The limited number and impact of current diagnostic techniques is largely responsible for the fact that many IFIs are only detected at quite a late stage. (2) The lack of reliability in diagnosis of IFIs has led to the categorization of patients according to the certainty of the diagnosis on their fungal infection, such as “possible”, “probable” or “proven” infection. The uncertainty of diagnosis together with poor prognosis have driven many researchers to come up with better antifungal strategies. Several studies have investigated the risk factors associated with IFI. Some of the common risk factors for developing IFI are summarized in Figure 1.3.
Due to the absence of standardization in the statistical analysis used in studies of risk factors for developing IFI, the results may be different from study to study. However, many studies of risk factors have revealed the trend for certain individuals to be at higher risk for acquiring IFI as a result of their underlying medical conditions.\textsuperscript{[17,18]}

With regard to risk factors and patients at high risk, patients in intensive care units (ICUs) are definitely on the top of the list that needs attention. Since \textit{Candida} species are the most common cause of IFIs in humans, IC also has long been established as a major problem in ICUs, with a ten times higher incidence in this setting than in general medical
and surgical wards.\textsuperscript{[19]} The Infectious Disease Society of America (IDSA) guidelines of 2009 outlined the therapeutic response to Candidemia and also highlighted the main risk factors including the use of broad-spectrum antimicrobials, the presence of central venous catheters, use of total parenteral nutrition, neutropenia, immunosuppression and renal replacement therapy in the ICU setting.\textsuperscript{[20]}

1.2 Diagnostic methods for fungal infections

Despite the emergence of new advanced techniques, traditional diagnostic tests for IFIs such as histology, microscopy and microbiological culture-based tests remain the foundation and routine methods to determine whether a subject is infected. For many superficial skin, nail and yeast infections, a clinical examination of the potentially infected person and microscopic examination of the samples (e.g. scrapings of scale, nail clippings, skin biopsy or swab from a mucosal surface) might be sufficient to determine if a fungal infection is present. In the case of IFIs, examinations of cultures of tissue, blood or other fluids are conducted to identify the presence of specific fungi. The sample collected needs to be transferred onto a medium such as Sabouraud's dextrose agar containing cycloheximide and chloramphenicol. If it is a mold that requires identification, cycloheximide is left out. Furthermore, susceptibility testing performed on fungi isolated from a culture is used to
determine which antifungal agent is the best to use for treatment. However, the conventional methods are associated with problems, such as low-yield and time-delay, which has significantly limited their impact on the management of potential fungal infection in clinical settings. Growing fungi, incubated in cultures at 25-30°C, may take several weeks for results to become available.

Due to the presence of severe thrombocytopenia, aggressive procedures such as biopsy of the infected site may have to be precluded. Although the culture-based tests are inexpensive and provide valuable material upon which to perform drug-sensitivity testing, cultures only become positive at a late stage of infection and organisms may take weeks to grow in culture, which would lead to the delay of diagnosis and therapy. Insisting on irrefutable evidence of deep tissue infection before any therapeutic intervention not only exposes many patients to invasive, potentially life-threatening tests but also results in an unacceptable delay of potentially life-saving therapy.

New diagnostic approaches have been developed with the knowledge of non-culture based methods, which are generally less invasive and usually provide an earlier diagnosis than morphologic evaluation by culturing. Recent advances in detecting fungal cell-wall components and genomic deoxyribonucleic acid (DNA) allow earlier diagnosis than conventional tests. Among all the new advanced
diagnostic technologies, the use of biomarkers has become prevalent in recent years, since it can provide critical information in a short period of time by relatively noninvasive specimen sources beyond the routine traditional methods. Two fungal biomarkers have been extensively researched and published over the last 20 years: galactomannan (GM) and 1,3-β-d-glucan (BDG).

1.2.1 GM antigen test

GM is a polysaccharide cell-wall component that is released by the fungus during its growth, especially for *Aspergillus* spp., in serum, bronchoalveolar lavage (BAL) fluid, and other body fluids. It is considered specific for aspergillosis because it contains higher levels of GM than other fungi species. The GM antigen test, which is now commercially available as a kit and marketed as the Platelia™ Aspergillus Ag (Bio-Rad), is a noninvasive technique used for the early identification of invasive aspergillosis (IA). The test is an enzyme-linked immunosorbent assay (ELISA), which employs the rat monoclonal antibody EB-A2 and recognizes the (1→5)-β-d-galactofuranosyl side chains of the GM molecule, and serial tests are recommended to attain the greatest yield. Results are expressed as the ratio (index) of the optical density (OD) obtained from the patient serum sample to that of the control serum containing 1 mg of GM per mL. Compared to conventional
approaches, an obvious superiority of the GM test is time-saving, since results can be available within 3 hours. \cite{24} A single result of GM index \( \geq 0.8 \) or two continuous results of \( \geq 0.5 \) should be treated as indication of IA and a full diagnostic process should be started. Furthermore, quantitative GM testing is a useful diagnostic tool, which is mainly used in high-risk haemato-oncological patients when it is combined with computed tomography (CT) imaging, in the detection of early IA. \cite{26}

However, limitations of this test include relatively low sensitivity (50–80\%) and cross-reaction with other fungi (e.g., \textit{Penicillium} species, \textit{Histoplasma} species, and \textit{Blastomyces} species). \cite{27} Due to the species-specificity of the assay, some emerging non-\textit{Aspergillus} mycoses cannot be detected by this method. It is also suggested in some studies that the GM assay has a limited impact on SOT recipients, due to relatively poor sensitivity and specificity, compared to hematology-oncology patients. \cite{28} However, it does not seem to make sense by comparing these two groups of patient populations in clinical settings. In addition, certain penicillin antibiotics have been reported to produce a false-positive GM test, likely because they are derived from \textit{Penicillium} species. \cite{29} Among these antibiotics, piperacillin-tazobactam (PT) (a widely prescribed drug combination in patients with cancer who have febrile neutropenia) was one of the antibiotic combinations identified as causing false positive results, which has been reported by several authors. \cite{30,31,32,33} Since the rat
monoclonal antibody has also been shown to recognize constituents of molds from other genera, such as *Penicillium* species, the antibiotics that are semisynthetic penicillins, including piperacillin, tazobactam, and amoxicillin, may be able to cross-react with the Platelia *Aspergillus* GM test.\textsuperscript{[34]} As a result, it has been indicated that maybe GM is carried through the production process of this antibiotic into batches designed for therapeutic use. Another study indicates that a positive Platelia *Aspergillus* test with PT is likely due to the presence of GM in PT rather than to a cross-reaction with the antibiotic.\textsuperscript{[35]} Some food products, including hospital meals, canned vegetables, pasta, and cereals, which may be contaminated with GM, can also be one of the sources of false-positive results. Also, damage to the intestinal mucosa could allow ingested GM to enter the bloodstream.\textsuperscript{[36]} The occurrence of false-positive GM assay results due to treatment with PT is a matter of concern because it may lead to unnecessary CT scans, undesirable (semi)-invasive investigations, over-treatment with expensive antifungal drugs that may produce toxicity and undesirable side effects. However, for all these years, opinions are divided on this point. Some studies indicated that they did not find any association between PT and GM positivity.\textsuperscript{[37,38,39]} In a previous study from Turkey, 28 of 43 sera (65.1\%) were positive in patients receiving concomitant PT in the absence of IA.\textsuperscript{[34]} While another institution from Turkey analyzed the false positivity of GM due to PT treatment with the
same method during the same period, surprisingly only 5 of 40 non-IA febrile episodes tested positive (false positive rate 12.5%). The conflicting results appeared to undermine the previous hypothesis regarding PT to be concerned as one of the major causes of false positivity. It was also reported in one study that they tested several PT batches and found that their GM content was reduced over the time of study. As a result, the authors speculated about the possibility of a modification in the manufacturing process to have occurred over time, resulting in better purity and less GM contamination. In the same study, besides the variable GM contamination in PT batches, their results also showed that the risk of false-positive GM tests can be minimized by performing blood sampling before PT administration and by using separate tubes of the central venous line for blood sampling and for administration of antibiotics. Some studies also come to the conclusion that the false positivity rate of GM antigen testing may be decreased by serial sampling by taking into account at least two consecutively positive values and by using a higher cut-off level (0.7 instead of 0.5).

1.2.2 BDG detection assay

BDG is a major cell wall polysaccharide that can be found in most fungi, with the exception of the Cryptococci, the zygomycetes, and Blastomyces dermatitidis, which either lack the glucan entirely or produce
it at minimal levels. BDGs are 1,3-β-D-glucopyranosyl polymers with randomly dispersed single β-D-glucopyranosyl units held by 1,6-β linkages, giving a comb-like structure. Although being common in fungi, yeasts, algae and bacteria, BDG cannot be found in prokaryotes and viruses, as well as human cells. Many studies indicated that glucans are released from fungal cell walls into the systemic circulation of patients with proven or probable IFIs, no matter if they were receiving antifungal medications. Therefore, the BDG’s presence in blood or other normally sterile body fluids may be a good serological marker of systemic fungal infection. Many BDG detection assays have been developed in the past two decades and some of them are commercially available: Fungitell (Associates of Cape Code, Inc., East Falmouth, MA, USA), Wako (Wako Pure Chemical Industries, Ltd., Tokyo, Japan), Fungitec-G (Seikagaku, Kogyo, Tokyo, Japan), and Maruha (Maruha-Nichiro, Foods Inc., Tokyo, Japan). However, the Fungitell assay is the only one that has been approved by the Food and Drug Administration (FDA) in 2003 for the diagnosis of invasive mycoses in serum in the United States. This assay is a chromogenic, quantitative enzyme immunoassay (EIA) designed to detect BDG by using purified, lysed horseshoe crab (Limulus polyphemus) amebocytes. These cells contain components of the Limulus clotting cascade, including Factors C and G, which initiate coagulation in the presence of bacterial liposaccharide and BDG, respectively. By
eliminating Factor C from the lysate, the activation of the cascade has been limited to BDG alone, which assures the specificity of the assay.\textsuperscript{[45]}

The use of BDG assay is included in the revised IFI diagnosis criteria of the European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) criteria. According to the new edition, a positive BDG result can be treated as mycological evidence of infection meeting their criteria.\textsuperscript{[46]} However, no guideline has been provided to standardize the use of BDG assays and also its analysis. As a consequence, inconsistency was found in results from various studies while comparing data, because different patient populations, cutoff values, and sites of infections (e.g. deep-seated colonization vs. fungal superficial colonization)\textsuperscript{[47]} have been taken into account in studies of BDG and other fungal biomarkers.\textsuperscript{[48]}

It has been reported in a meta-analysis of 15 studies assessing the overall accuracy of BDG in the diagnosis of IFI that BDG assays have a high specificity in patients with hematologic disorders but relatively low performance in SOT recipients.\textsuperscript{[49]} Although the number of measurements required for defining a positive BDG test result has not been standardized yet, compared to a single positive result, according to the same study,\textsuperscript{[49]} requiring two consecutive BDG results reduced the overall sensitivity value, but enhanced the overall specificity value.
In a study about the kinetics of BDG in persistently neutropenic rabbits with IA, the results suggested that both cell wall components (GM and BDG) appeared to be comparable and provided similar information regarding the extent and stage of infection. For the models with invasive pulmonary aspergillosis, concentrations of both biomarkers begin to rise within the first 24 h of infection, well before pulmonary infarction is evident, supporting the concept that these molecules, when circulating, signal invasive disease almost immediately after host defenses are breached.\[^{50}\] Another intriguing meta-analysis, which included six cohort studies, reported a diagnostic odds ratio (DOR) of 111.8 versus 16.3 for the presence of IFIs in neutropenic hemato-oncological patients following two consecutively positive BDG assays compared to a single positive BDG assay.\[^{51}\] Both the analysis of the kinetics of BDG levels and DOR results in the meta-analysis suggest that at least two sequential positive BDG results are required for indirect mycological criteria to allow possible invasive fungal diseases to be upgraded to probable invasive fungal diseases and also for higher diagnostic performance and better homogeneity of test results.

Recently, a meta-analysis, which covered 28 individual studies, provided a new direction in this area, i.e., assessing the diagnostic accuracy of serum BDG for IFIs on different cutoff values. The cutoff value of 60 pg/mL has the best diagnostic accuracy according to the
EORTC/MSG criteria, and it also shows the best diagnostic accuracy with the Fungitell assay compared to other BDG detection assays. The area under the curve of the summary receiver operating characteristic (AUC-SROC) analysis has been recommended to represent the performance of a diagnostic test, based on data from a meta-analysis. Therefore, sensitivity, specificity, DOR and AUC-SROC were estimated in this study, based on different cutoff values. When the AUC-SROC is between 0.80 and 0.90, it is usually considered as a good diagnostic test accuracy, and a value >0.90 indicates a very high overall diagnostic accuracy of the test. In their general analysis, patients who had proven or probable IFIs were compared with patients who did not have IFIs for serum BDG measurement with the AUC-SROC being 0.8855. It suggested that the BDG assay had a good diagnostic accuracy for the diagnosis of IFIs. When it comes to the diagnostic accuracy of different cutoff values of BDG, the analysis of cohort studies indicated that the cutoff value of BDG at 80 pg/mL had the best diagnostic accuracy (with an AUC-SROC of 0.9284), whereas the case-control studies indicated that the cutoff value of 20 pg/mL had the best diagnostic accuracy (with an AUC-SROC of 0.9943). When using the EORTC/MSG criteria as a reference standard, the cutoff value of 60 pg/mL has the best diagnostic accuracy, with an AUC-SROC of 0.8804.
Being one of the useful noninvasive diagnostic tools, a key advantage of the BDG assay is the required specimen source being serum, which is readily available and easily accessible, regardless of patient conditions. However, similar to GM assays, BDG assays also suffer from false positivity, which may result from: glucan-contaminated blood-collection tubes and surgical gauze dressings; dialysis with cellulose membranes; bacteremia due to several gram-positive organisms, particularly \textit{Streptococcus pneumoniae}; use of products with cellulose depth filters such as albumin; gut inflammation; and use of antibiotics such as amoxicillin-clavulanate.\textsuperscript{52,53,54}

Although it did not improve the sensitivity of each test, the combination of BDG and GM detection was very useful in confirming the existence of IA. Furthermore, the use of both assays could be useful to identify the false positive results as well, due to discrepancies in positivity of each test.\textsuperscript{49} A number of groups have reported that among critically ill patients with proven or probable IFIs, many developed detectable BDG antigenemia prior to the onset of clinical symptoms or radiologic signs or the return of positive culture results. The percentages of patients in whom this occurs vary between studies (64 to 87%), as do the numbers of days between BDG and culture (blood, biopsy, or BAL fluid) positivity (1 to 10 days).\textsuperscript{43,55,56,57,58} However, positive results from the tests still need verification in the course of systematic monitoring of consecutive serum
samples to exclude false-positive results and warrant the use of other diagnostic methods, for example radiological studies, including high resolution CT (HRCT). In patients with proven IA, the BDG antigen level corresponded with the response to the antifungal therapy. In patients with regression of the illness, a decrease in serum BDG was noted but continuously high levels of antigen were observed in patients not responding to therapy, so tracking quantitative values following initiation of antifungal therapy may be used as a prognostic marker for patient response. [43]

Although biomarkers are prevalent clinically in the care of high-risk patients with suspected IFI, biomarkers fall short in many respects. As mentioned earlier, GM assays have a high sensitivity among patients with hematologic malignancies (72%) and among bone marrow transplant recipients (82%), but it is decreased among SOT recipients (22%). [28] It also suffers from false-positive or false-negative results, because certain antibiotics, fungal infection due to *Histoplasma* species, and even the ingestion of certain foods may increase GM levels, whereas antifungal therapy may rapidly decrease GM levels. Meanwhile, BDG is a helpful serological marker of systemic fungal infection, but it is nonspecific, since it can be found in many different fungal cell walls, such as those of *Fusarium* species, *Acremonium* species, or *Pneumocystis jirovecii*, and even certain foods. In addition, biomarkers can neither detect all fungal
pathogens nor identify to the species level and sometimes cannot even reliably identify organisms to the genus level. Therefore, biomarker assays (both GM and BDG) are recommended to be used together with other diagnostic tools as corroborative evidence.

1.2.3 Polymerase chain reaction (PCR) assay

The PCR method for DNA amplification was developed by Kary Mullis and colleagues in 1984 and was rapidly adapted to detect a variety of infectious agents, particularly viruses. Along with the progress in PCR in recent years, it has become more popular in detecting fungal pathogens in human infections. Clinical samples such as blood and BAL fluid often contain only a small number of fungal cells, which may lead to a low sensitivity in other routine assays. However, PCR can be used to amplify the number of fungal DNA in samples providing better performance in other diagnostic tests. In order to achieve the amount for PCR-based fungal diagnostic assays, extraction methods need to be applied to lyse all available fungal cells to maximize DNA quantity. Appropriate selection of the target gene is of great importance because of the opportunity it can provide to increase the sensitivity of a PCR assay. The detection limits of PCR assays can be a few gene copies per reaction, providing the ability to detect a fraction of an organism when targeting genes present in multiple copies per fungal genome. In fact, targeting
multicopy genes has the advantage of increasing their sensitivity, compared with single-copy genes. The common multicopy targets are the 18S ribosomal ribonucleic acid (rRNA) and 28S rRNA genes, the internally transcribed spacer (ITS) regions, and mitochondrial gene regions.

The key for the PCR process is a uniquely synthesized pair of oligonucleotide primers that flank and define the DNA segment of interest. The highly conserved regions of the fungal rRNA gene are used to “prime” the synthesis of the remainder of the gene. With the fungal DNA extracted from the fungi or clinical sample, a DNA polymerase is added to react with the target DNA strand to which the primer has bound as a template to synthesize a complementary strand of DNA (cDNA). The source or product of amplification or replication is also known as an amplicon. There are several different approaches for detection and analysis of the targeted amplicon. First of all, the most classical approach for amplicon detection is agarose gel electrophoresis, which is capable of separating amplicons according to their specific length. However, due to the inability to differentiate amplicons with identical or similar lengths, this procedure has a deficiency in specificity. In order to get better interpretation of data, oligonucleotide probes are specifically designed to bind complementary sequences in the target DNA, showing characteristic dye chemistries, including fluorescence resonance energy transfer,
hydrolysis, molecular beacon, and Scorpion systems. The amplified products are hybridized to DNA probes specific for each organism, allowing for a greater degree of specificity than the use of primers alone. \[63\] Another method to identify fungal species is amplicon sequencing, when amplicon contains species-specific base pairs. Even if only minor differences exist, one base pair between different species are often sufficient for identification. After sequencing, comparative analysis of the nucleotide sequence is performed to find a match in public databases. \[64\]

Among all these approaches, real-time PCR has become a research hot topic in recent years. Real-time PCR technology combines nucleic acid target amplification using standard PCR chemistry and detection using fluorescent probes in a simultaneous, single-well reaction. \[65\] Compared to conventional PCR testing, real-time PCR assay can decrease time for testing by eliminating the necessity to perform post-amplification processing and detection. Since the real-time PCR procedure can be completed in a single, closed-reaction vessel, it can reduce the possibility of environmental contamination with amplified nucleic acids, which is particularly important for fungal diagnostics. \[66\] It has been reported that *Aspergillus* species DNA can be detected by PCR-based assays of blood for a mean duration of 14 days before the clinical diagnosis of IA. \[67\] PCR positivity can also precede positive GM assay results (median, 17 days; range, 4–63 days) or positive CT findings (median, 8 days; range,
1–84 days), which shows the outstanding performance of PCR-based assays in the ability of providing earlier diagnosis.\textsuperscript{[68]}

Due to many different reasons and risk factors, the epidemiology of fungal infections is rapidly evolving, and non-\textit{Aspergillus}, non-\textit{Candida} species and other rare fungi have emerged as major opportunistic pathogens with even more difficulties in diagnosis and treatment. In a recent study with 51 patients involved, a considerable number of fungi (8 of 18, 44.4\%) other than major ones such as \textit{Aspergillus} and \textit{Candida} species were identified by PCR, when reliable serological diagnostic methods are generally absent for these organisms.\textsuperscript{[69]} Therefore, DNA analysis might be the only diagnostic tool when no information can be gained from the culture study, which not only indicates the importance of PCR technology but also attracts our attention to the further development of DNA analysis.

Nevertheless, there are still some major shortcomings in PCR-based assays that might hinder the implementation of its clinical utility. First, there is lack of standardization for the use of PCR-based assays and the EORTC/MSG did not include PCR tests in the diagnostic criteria of probable IFI. As a result, different laboratories use different primer pairs, various interpretations of positive results and a wide range of amplification protocols.\textsuperscript{[61,64,70]} Second, the impact of PCR-based assays on clinical decisions is limited by the non-negligible percentage of false-
positive results due to colonization or contamination of the sample. \[59\] The factors contributing towards false-positivity can be divided into procedural false positivity and clinical false positivity. Procedural false positivity can be caused by contamination from the environment, previously amplified PCR products, or cross-reactivity of PCR primers and probes with non-target fungi or other organisms. On the other hand, clinical false positivity could be caused by colonization of human tissue surfaces with fungi. Whereas it is not a reflection of inadequacies in assay design or protocol, since the assay has detected something that it was designed to do. \[65,71\] To avoid or at least reduce the possibility of false positivity, more attention should be paid on adopting rigorous quality control measures, optimizing DNA extraction methods and PCR platforms.

1.3 Antifungal agents

Although the number of agents available to treat fungal diseases has increased by 30% since 2000, the medications that have been approved for clinical use are still less than 20. Depending on the modes of action, current antifungal agents fall into the following three categories, polyenes, azoles and echinocandins.
1.3.1 Polyenes

As the principal member of the polyene class of antifungals, amphotericin B (AmB), 1, deoxycholate is a broad-spectrum antifungal agent (the structure of AmB is shown in Figure 1.4). AmB has been used as the standard treatment for IFIs for more than 30 years \textsuperscript{[13]} by acting on ergosterol of the fungal cell membrane. Since ergosterol is the main sterol of the fungal cell, by forming a complex with ergosterol, polyenes can thereby perturb the fungal plasma membrane function, which can result in increased membrane permeability, leakage of the cytoplasmic contents and ultimately death of the fungal cell. \textsuperscript{[24]} The antifungal selectivity of AmB is based on the conformational difference between the fungal ergosterol molecule and the mammalian cholesterol. Ergosterol has a cylindrical three-dimensional structure, while cholesterol has a sigmoidal shape. \textsuperscript{[72,73]} However, the selectivity is low, which leads to toxicities for mammalian cells, particularly causing nephrotoxicity. Moreover, AmB has also been associated with other adverse effects including low blood potassium, infusion-related acute reactions (such as chills, fever, hypoxaemia, and hypotension), especially when administered over a short period of time. \textsuperscript{[74]}

In an effort to reduce AmB toxicity, a variety of its lipid preparations have been introduced, including AmB lipid complex, AmB colloidal dispersion and liposomal AmB (L-AmB). \textsuperscript{[75]} After enclosing the
amphotericin molecule within a liposome or other lipid carrier, to release free amphotericin, it needs to be dissociated from the AmB-lipid complex within the body. Therefore, it may reduce the time of exposure of amphotericin resulting in diversion from potentially vulnerable tissues, most importantly, the kidney.\textsuperscript{[76]} In a systematic review of the literature, studies showed that lipid-based formulations significantly reduced all-cause mortality risk by about 28\%, compared with conventional AmB.\textsuperscript{[77]} It also has been reported that the use of lipid AmB (versus AmB deoxycholate) can provide better outcomes and clinical benefits in SOT recipients with cryptococcal meningitis.\textsuperscript{[78]} So far, despite the higher costs, for the treatment of many IFIs, an AmB lipid formulation seems to provide a safer alternative than AmB deoxycholate, with at least equivalent efficacy. However, due to the limited data available regarding therapeutic equivalency between lipid AmB and conventional AmB, more well designed, randomized trials are needed to compare these formulations in different clinical settings.\textsuperscript{[79]}

![Figure 1.4. Structure of amphotericin B (AmB) I.](image URL)
1.3.2 Azoles

While the use of AmB has been limited by its side effects, the arrival of azoles such as fluconazole and itraconazole brought a major advance for the treatment of fungal infections. Since it was first introduced for clinical use in the early 1980s, theazole class of antifungal agents has rapidly become the most widely used in antifungal therapy and prophylaxis. \[^{80}\] Similar to the polyenes, azoles also take effect on ergosterol, although via a different mechanism. In addition to being the major component of fungal cell membrane, ergosterol participates in the regulation of membrane fluidity, asymmetry and integrity, as well as stimulating fungal growth and proliferation. \[^{81}\] The primary molecular targets of azoles are the P450 enzymes that catalyze the oxidative removal of the 14α-methyl group of lanosterol. \[^{82}\] Consequently, the main effect of azoles is to inhibit 14α-demethylation of lanosterol in the ergosterol biosynthetic pathway, resulting in a decreased ergosterol synthesis and a concomitant accumulation of 14-methylated sterols, which changes the permeability and fluidity of the fungal membrane. \[^{83}\] Meanwhile, due to the fact that the same P450 enzymes are responsible for production of cholesterol in mammalian liver cells, azoles are also able to block this biosynthesis, which is directly associated with their adverse effects. \[^{84}\]

On the other hand, since one of the 14-methylated intermediates of lanosterol, 14-methyl-ergosta-8,24(28)-dien-3,6-diol, is toxic, some
authors have suggested that the accumulation of toxic intermediates may have played the key role for azoles to inhibit fungal growth. [85]

The first generation of antifungals in this class was the N-substituted imidazoles introduced in the late 1960s. Over the last few decades, the imidazole has been replaced by a triazole nucleus as the active pharmacophore, to enhance the specificity of coupling with fungal P450 enzymes, which leads to the introduction of triazole antifungals like fluconazole, itraconazole and the recent triazole derivatives, such as voriconazole and posaconazole. [83] After being metabolized by CYP450 enzymes in the liver, the inactive metabolites of azoles are eliminated via the urinary and gastro-intestinal tracts. Due to this metabolic pathway, there is a long list of drug-drug interactions, including the use of benzodiazepines, prednisolone, methyl-prednisolone, digoxin, phenytoin, carbamazepine, cyclosporine, rifampin, and other drugs in common use, which can cause problems for physicians in treating critically ill patients who receive multiple medications. [81,86,87,88]

Resistance to azoles has already been observed and well documented. [24] A large number of studies have been performed on the mechanisms of antifungal resistance. As for Candida species, there are four principal mechanisms suggested with respect toazole resistance. [89,90] Firstly, many of the studies indicated the induction of efflux pumps, which leads to decreased drug concentrations at the target within the fungal cell. [89]
Upregulation of efflux pumps encoded by either multidrug resistance (MDR) or Candida drug resistance (CDR) genes is usually associated with drug resistance with some differences according to species.\textsuperscript{91} In addition, point mutations in the gene (ERG11) encoding for the target enzyme lanosterol C14α-demethylase lead to an altered target with decreased affinity or incapacity for azoles to bind to the enzymatic site.\textsuperscript{92} Thus, overexpression of the mutated gene or upregulation of the altered target enzyme can also become a cause of resistance, which results in higher levels of azole cellular targets that cannot be bound by therapeutic concentrations of azole antifungals.\textsuperscript{89} As the last potential mechanism of azole resistance, the development of an alternative pathway of sterol synthesis can be caused by another mutation on the ERG3 gene, which leads to replacement of ergosterol with 14α-methylfecosterol.\textsuperscript{93} The unusual accumulation of ergosta-7,22-dienol-3β-ol in azole-resistant C. albicans clinical isolates allows the cells to bypass the synthesis of the toxic sterol and thereby makes the effects of azoles on the ergosterol biosynthetic pathway negated.\textsuperscript{94} Due to the ERG3 mutation, the fungal cell membrane that cannot be affected by azole does not contain ergosterol, and this absence of ergosterol provides a mechanism for cross-resistance to polyene antifungals.\textsuperscript{95} Fluconazole 2, voriconazole 3 and posaconazole 4 are important members in the azole class and their structures are illustrated in Figure 1.5.
Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents

Figure 1.5. Structures of Fluconazole 2, Voriconazole 3 and Posaconazole 4.

Fluconazole (Diflucan®)

Although some newer antifungal agents in theazole class have been introduced to clinical use, fluconazole still remains one of the most frequently prescribed triazole antifungal agents because of its great bioavailability and low toxicity, combined with low cost and availability as both intravenous and oral formulations. Among azole antifungals, fluconazole is the most frequently used agent for prophylaxis and EAT, which is appropriate for patients with low risk for mold pathogens (e.g. *Aspergillus* species).
The oral bioavailability of fluconazole is generally good with more than 80% of ingested drug being found in the circulation. Moreover, fluconazole is also characterized as the only azole to achieve therapeutic levels in urine, with 60% to 70% of the drug being excreted unchanged in the urine. [98] For many antifungal agents, it is difficult for them to penetrate the blood-brain barrier and achieve therapeutic cerebrospinal fluid (CSF) concentrations, since they are relatively large molecules. Noteworthily, fluconazole presents a relatively large volume of distribution with good penetration into various tissues including penetration into the CSF, which enables it to achieve good levels in the brain and CSF. [99,100] However, although fluconazole is active against most Candida spp., it is inactive against Candida krusei and Candida glabrata isolates. [101] Fluconazole also shows no activity against Aspergillus spp., Fusarium spp., Scedosporium spp., or the Zygomycetes, which greatly limits its clinical use. [102]

**Voriconazole (Pfizer®)**

Voriconazole is a second-generation azole antifungal agent and a synthetic derivative of fluconazole with broadened antifungal spectrum. Among all of the second-generation triazoles, voriconazole was the first to be approved by the FDA for the treatment of IA, serious infections caused by Fusarium and Scedosporium apiospermum, and fluconazole-resistant invasive Candida infections. [103] By adding an α-methyl group
and replacing one of the triazole moieties with fluorinated pyrimidine, voriconazole exhibits a broader spectrum of activity when compared to fluconazole. Voriconazole is active against *Aspergillus* spp., *Fusarium* spp. and all *Candida* species (including the fluconazole resistant or less susceptible spp. of *C. glabrata* and *C. krusei*), except Zygomycetes.

Similar to fluconazole, voriconazole is available as oral and intravenous forms and the latter form depends on sulfobutyl ether β-cyclodextrin sodium (SBEC) for solubility. Since SBEC is excreted via the kidneys, where accumulation of SBEC could occur, dose adaptation is required in cases of renal impairment. The oral bioavailability of voriconazole is more than 90% when the stomach is empty, but it decreases when food is present. Fatty foods have been found to reduce bioavailability by 80%. Voriconazole is distributed widely in humans with a reasonable penetration of the blood-brain barrier and CSF levels being around 50% of plasma levels. Due to the fact that the efficiency and distribution of a drug may be affected by the degree to which it binds to the proteins within blood plasma, it is a very important factor in determining the amount of active drug present at a given site of infection. As for voriconazole, it is 58% protein bound and has a large volume of distribution, while polyene agents and many other azole antifungals are highly protein bound (>90%).
Voriconazole undergoes extensive hepatic metabolism via the CYP450 enzymes, primarily by CYP2C19 and to a lesser extent by CYP2C9 and CYP3A4. Several metabolites are excreted in urine, with <2% being unchanged. Unfortunately, none of the voriconazole metabolites exhibit antifungal activity. Due to the metabolic pathway by CYP450 isoenzymes, the potential for drug-drug interactions with voriconazole is high. Specifically, inducers of CYP450, such as rifampin, long-acting barbiturates, and carbamazepine, can cause decreased voriconazole concentrations, so that concurrent use of these drugs with voriconazole should be avoided. On the other hand, voriconazole can also interfere with the metabolism of several other drugs through inhibition of either the CYP3A4 or the CYP2C9 pathway, and coadministration can lead to toxic levels of those common drugs.

Although voriconazole is generally well tolerated, there is a common side effect associated with the use of voriconazole, being not previously noted with other azoles, a reversible disturbance of vision (photopsia). This side effect occurs in about 30% of patients but rarely leads to discontinuation of the drug, since the visual effect is transient and no permanent damage to the retina has been noted. Other well-known adverse effects of voriconazole include skin rash (phototoxicity-related rash sometimes) and transaminase elevation, which are all reversible after discontinuation of the therapy. Despite the side effects it may
suffer from, voriconazole has become the first choice of antifungal agents with regard to IA in most of the cases. According to a multicenter, randomized, comparative study of IA with great significance, voriconazole was superior to AmB in efficacy (53% vs. 32% response) and resulted in improved 12-week survival (71% vs. 58%), which makes voriconazole the primary treatment choice for IA and oral voriconazole is preferred for ‘step-down’ or maintenance therapy.

**Posaconazole (Noxafil®)**

Being approved by the FDA in 2006, posaconazole is characterized as a lipophilic second-generation of the antifungal triazole with a broad spectrum of activity. Since posaconazole has a low solubility in aqueous and acidic media, no intravenous formulation is available. To determine what oral formulation would provide better bioavailability, a suspension of posaconazole was compared with the tablet formulation. It turned out that being administered as a cherry-flavored 40-mg/mL suspension using polysorbate 80 as an excipient helps lower sedimentation of solid particles because of the greater surface area and enhanced gastric mixing of the drug. Its oral bioavailability also varies depending on dosage regimen and food intake, which is potentially problematic for clinical use. Unlike the high bioavailability of voriconazole with an empty stomach, food intake significantly increases the oral bioavailability.
of posaconazole, with either a nonfat or high-fat meal (168% and 290%, respectively) or with a nutritional supplement.\textsuperscript{[121,122]}

Posaconazole has a large volume of distribution after oral administration suggesting extensive extravascular distribution and penetration into intracellular spaces.\textsuperscript{[123]} In general, posaconazole primarily circulates in plasma and then is widely distributed to the tissues and is slowly eliminated. However, posaconazole is highly protein bound (>98%), predominantly to albumin and binding is concentration independent. As a result, the penetration of posaconazole into CSF was found to be poor.\textsuperscript{[124]} Although posaconazole is eliminated primarily unchanged, its main metabolites come from glucuronidation produced through Phase II biotransformations via uridine diphosphate (UDP) - glucuronosyltransferase (UGT) enzyme pathways.\textsuperscript{[125]} According to a study of eight healthy male subjects, elimination of posaconazole occurred primarily through fecal excretion (79.6%), mainly as unchanged, and to a lesser extent through the urinary route (14%).\textsuperscript{[126]} Since posaconazole is metabolized by the liver and mainly excreted in the faeces, the limited renal elimination allows for the use of posaconazole without dosage adjustment in patients with renal impairment, which makes it an appropriate alternative to AmB for patients with renal dysfunction.\textsuperscript{[124,127]} Unlike voriconazole, which is a substrate and an inhibitor of CYP3A4, CYP2C9 and CYP2C19, posaconazole is not
significantly metabolized through the CYP450 enzyme system. However, posaconazole has been found to greatly decrease the hepatic activity of CYP3A4, which can inhibit the clearance of drugs metabolized by CYP3A4 resulting in increased plasma concentrations of these drugs. Depending on the chemical structure of the substrate and the CYP isoforms involved, the degree of inhibition varies. For instance, coadministration of posaconazole with some of the CYP3A4 substrates is contraindicated due to the risk of corrected QT interval (the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle) prolongation, while for some other CYP3A4 substrates, the doses should be reduced to counteract the increased exposure and the whole-blood concentrations of these agents should be carefully monitored.

Overall, posaconazole appears to be well tolerated in clinical trials so far and rarely requires discontinuation because of adverse effects. The most frequently reported side effects have been associated with gastrointestinal disturbances (14-18%, nausea, vomiting, abdominal pain, diarrhoea, etc.) and hepatic toxicities (3%, transaminase elevation and hyperbilirubinemia). In a long-term safety study, 428 patients with refractory IFIs (n = 362) or febrile neutropenia (n = 66) who received posaconazole, 38% of the patients reported treatment-related adverse effects. It is noteworthy that among all of the 428 patients, 109 of them received posaconazole therapy for more than six months and no severe
side effect was observed, suggesting that posaconazole is well tolerated for long-term use. [133]

As the first-line choice for prophylaxis of invasive *Aspergillus* and *Candida* infections in severely immunocompromised patients, posaconazole has been proven to be effective by several studies. In a double-blind multicenter study, 600 allogeneic HSC recipients with graft-versus-host disease were enrolled. Based on the situation that patients had received intensive immunosuppressive therapy, posaconazole was compared with fluconazole for prophylaxis of invasive mycoses. [134] It was shown that posaconazole was as efficacious as fluconazole in preventing all IFIs (5.3% and 9.0%, respectively; P=0.07), and was superior to fluconazole in preventing IA with significantly lower incidence in the posaconazole group (2.3% vs. 7.0%; P=0.006) at the end of the 112-day treatment period. Posaconazole was also found to be superior to fluconazole in preventing breakthrough IFIs (2.4% vs. 7.6%, P=0.004), particularly in cases of IA (1.0% vs. 5.9%, P = 0.001). Although there was no significant difference in overall mortality, a significant difference was observed in the number of deaths from IFIs, which was much lower in the posaconazole arm than fluconazole arm (1% vs. 4%, P=0.046). Another multicenter, open-label study evaluated posaconazole oral suspension as salvage therapy for IA, which included 107 posaconazole recipients and 86 control subjects (control subjects
could not receive any antifungal agents as standard therapy that were investigational at the time of their treatment, i.e., voriconazole or an echinocandin). [135] Patients were enrolled to receive posaconazole for salvage treatment if they were confirmed to have a diagnosis of IA, and if they were refractory to at least seven days of antifungal therapy or were intolerant of conventional therapy. The overall success rate was 42% (45 of 107) for posaconazole recipients and 26% (22 of 86) for control subjects (P=0.006). The results also showed that posaconazole appeared to provide better survival rates, since in the arm of posaconazole the cumulative rates of survival at 30 days and at the end of therapy were 74% and 38%, respectively; for control subjects, those survival rates were 49% and 22%, respectively. Based on the favorable results in both efficacy and safety, the current dosage regimen for posaconazole is 200 mg three times daily for prophylaxis, and 800 mg divided in two or four doses in the salvage setting.

1.3.3 Echinocandins

The changing pattern of fungal infections and increasing incidence of azole-resistance have led to the necessity of finding a new drug target for antifungal therapy. Notably, as a new drug class, the echinocandins, which aim at a drug target different from polyenes and azoles, have been approved for clinical use. [136] Being rigid structures, fungal cell walls are
composed of large polysaccharides BDG, 1,4-β-D-glucan, 1,6-β-D-glucan, chitin, mannan or GM, and α-glucans and various glycoproteins. The target for echinocandins is the complex of proteins responsible for synthesis of BDG. By inhibiting this glucan synthase, it can impair cell wall integrity and ultimately lead to osmotic lysis and death of susceptible fungal cells. Therefore, the activity spectrum of echinocandins is limited to fungi that rely on these types of glucan polymers, which makes them less broad than the activity spectra of polyene orazole agents. Still, the echinocandins have shown fungicidal activity against many pathogenic fungi such as *Candida* spp., *Aspergillus* spp. and *Pneumocystis jirovecii*. Owing to their completely different drug target and mechanism of action, echinocandins are broadly active against azole-resistant *Candida* spp.

The echinocandins are semisynthetic amphipilic lipopeptides being composed of a cyclic hexapeptide core with an alkyl side chain (see Figure 1.7). As a result of the structural characteristics, the echinocandins are usually large molecular weight compounds (around 1200).

The antifungal activity of echinocandins was discovered from prototypes, echinocandin B 5 and aculeacin A 6, by random screening in the 1970s. The structures are shown in Figure 1.6. Both prototypes were obtained from products of fermentation of some fungi such as *Zalerion arboricola* or *Aspergillus nidulans* var. *echinulatus*. With the
knowledge that both echinocandin B and aculeacin A showed some antifungal activity, further studies regarding antifungal efficacy and mechanism of action were performed. Later, studies found that besides the direct fungicidal and fungistatic activities, echinocandins also have immunomodulatory effects. Inhibition of the biosynthesis of BDG synthase disrupts the equilibrium required to maintain cell wall structure, resulting in increased β-glucan exposure, which exhibits immunostimulatory properties. Due to the additional exposed antigens, antibody deposition will be triggered, which will cause further recognition by the host immune system.

Figure 1.6. Structures of echinocandin B 5 and aculeacin A 6.
At present, there are three members in use in the class of echinocandins: caspofungin 7, micafungin 8 and anidulafungin 9. The structures are shown in Figure 1.7. All echinocandin preparations currently in use are for intravenous use only because of the poor oral bioavailability (only around 3%). In addition, echinocandins are highly protein bound (from 85% to 99%), which limits the amount of free drug available for activity. Echinocandins undergo degradation mainly in the liver by hydrolysis and N-acetylation rather than through CYP450 (to a lesser extent). For caspofungin, it is metabolized very slowly, because of the hepatic uptake after initial distribution, and it also undergoes degradation producing an inactive open ring compound in the liver. Two inactive metabolites are produced during the metabolism, which are excreted in the bile and feces. Owing to the metabolic pathway of caspofungin, dosage reduction is recommended for patients with severe hepatic dysfunction. Micafungin undergoes non-oxidative metabolism to produce two metabolites. One of the metabolites is formed as the side chain of micafungin is hydrolyzed by CYP isoenzymes (mainly CYP3A). Although micafungin is a substrate for, and a weak inhibitor of, CYP3A4 in vitro, hydrolysis plays only a minor role in the metabolism of this drug. The main metabolic pathway of micafungin is facilitated by arylsulfatase with further decomposition by catechol-O-methyltransferase. Unlike the two members in this class discussed above,
more than 90% of anidulafungin goes through non-enzymatic degradation resulting an inactive open-ring peptide that appears to be further degraded by plasma peptidases. There is no hepatic metabolism mediated by CYP450 observed. As for elimination, anidulafungin is eliminated by fecal excretion, mainly as degradation products via biliary system, rather than passing into urine. In addition, none of the members in the class of echinocandins can be dialyzed, and so no dosage adjustment is necessary for patients having renal replacement treatment.

Figure 1.7. Structures of Caspofungin 7, Micafungin 8 and Anidulafungin 9.
Although fungi are eukaryotes like human beings, cell walls and targets of echinocandins do not exist in mammalian cells, which attributes to the minimal toxicity of this class of antifungal agents.\textsuperscript{[103,145]} Therefore, compared with AmB, whether in complex with lipid or not, the echinocandins exhibit a better safety profile.\textsuperscript{[121]}

However, histamine-mediated infusion-related reactions, such as facial swelling, rash, and vasodilatation, have been observed when rapid administration of echinocandins is given. Such reactions seem to be easily relieved by slowing the rate of infusion or premedicating with an antihistamine.\textsuperscript{[152]} Since the echinocandins are poor substrates for the CYP450 enzymes, and are not substrates for intestinal or tissue P-glycoprotein, fewer drug interactions have been reported for these compounds than for theazole antifungals.\textsuperscript{[139]} Nevertheless, there are still some drug interactions that have been documented. The concentration of caspofungin can be diminished when administrated with CYP450 inducers, such as rifampin and phenytoin, which merits a slight increase in dose.\textsuperscript{[153]} Micafungin has shown weak inhibitory effects against CYP3A4 causing increased serum concentrations of substrates of this enzyme, like sirolimus and nifedipine.\textsuperscript{[121,139]} Yet, anidulafungin does not seem to exhibit these CYP450-related interactions.\textsuperscript{[151]}

Since being approved for clinical use, the echinocandins are considered to be the choice of treatment for IC due to their broad
antifungal spectrum and fungicidal activity against various species of
*Candida*. Along with the findings of many clinical studies and trials with
regard to echinocandins, indications appropriate for oesophageal
candidiasis, IC and candidemia, IA, and prophylaxis of IFIs have been
explored as an intravenous drug.\[^{145}\]

In 2001, caspofungin became the first member in the class of
echinocandins approved by the FDA for treatment of patients with IA
who cannot tolerate or who are refractory to other antifungal therapies. It
was also approved for the EAT of fungal infections in febrile neutropenia,
candidemia and the following *Candida* infections: oesophageal candidiasis,
intra-abdominal abscesses, peritonitis and pleural space infections.
\[^{103,154,155,156}\] In a randomized double-blind multicenter trial of caspofungin
versus AmB for treatment of IC (mainly candidemia), caspofungin was
found to be as effective as AmB but less toxic.\[^{155}\] Among patients who
received intravenous antifungal therapy for 10 days, the rate of favorable
response was 73.4% in the caspofungin group and 61.7% in the AmB
group suggesting that caspofungin is at least equally efficacious as AmB.
\[^{155}\] On the other hand, the number of discontinuation due to adverse
events was significantly higher in the AmB arm than that in the
caspofungin arm (23.2% vs. 2.6%, respectively), which reveals the
superiority of caspofungin on toxicity profiles compared to AmB.\[^{155}\]
Among three members of echinocandins, caspofungin is the only one that
has been studied in a large randomized double-blind controlled trial (RCT) for febrile neutropenia in which over 1000 patients were enrolled. \textsuperscript{[157]}

Both efficacy and safety of caspofungin have been assessed and compared with L-AmB for EAT in the study. The overall success rates were 33.9\% for caspofungin and 33.7\% for L-AmB, showing similar efficacy, while discontinuation occurred less often in the caspofungin group than in the L-AmB group (10.3\% vs. 14.5\%, P=0.03). \textsuperscript{[157]}

Caspofungin has also been studied as salvage therapy for IA in a noncomparative, multicenter clinical trial in which 83 patients were involved, who were either refractory to (71, 86\%) or intolerant of (12, 14\%) previous antifungal therapy. \textsuperscript{[156]} Among the 83 patients who received at least one dose of caspofungin, a favorable response was observed in 37 (45\%) patients, which actually led to the first approval of the use of an echinocandin for treatment of IA in patients intolerant of or refractory to conventional antifungal treatment by North America and the European Union. \textsuperscript{[156]}

The second echinocandin, micafungin, was approved in 2005 initially for the treatment of esophageal candidiasis and prophylaxis of invasive \textit{Candida} infections in patients undergoing HSC transplantation (HSCT). \textsuperscript{[103]} Of echinocandin class, only micafungin has been formally evaluated, in two randomized trials for antifungal prophylaxis, and found to be effective in preventing invasive \textit{Candida} infections and also be a
potential alternative to fluconazole as prophylaxis for IA.\textsuperscript{[158]} Since it is common to use fluconazole for antifungal prophylaxis, two randomized, double-blind, multicenter, comparative trials of micafungin and fluconazole were designed to compare their efficacy and safety profile with different dosages of micafungin (a daily dose of 50 mg, 100 mg or 150 mg) in the two studies. Both studies defined success as absence of suspected, proven, or probable IFIs through the end of prophylaxis therapy and no proven or probable IFI through the end of the 4-week period following treatment.\textsuperscript{[159,160]} In the first study, either 50 mg of micafungin or 400 mg of fluconazole was administered once daily as a one-hour infusion.\textsuperscript{[159]} A higher overall success rate was observed in the micafungin group (80\%) than that of the fluconazole group (73.5\%).\textsuperscript{[159]} In the other study, patients were randomly assigned with either micafungin 150 mg or fluconazole 400 mg once daily.\textsuperscript{[160]} Although the molar amount of micafungin and fluconazole (molecules, mole as unit) were not mentioned in the literature, it would have been better to compare their molar amount of substance, instead of their physical weights, due to a significant difference in their molar weights. Therefore, the comparison of 150 mg micafungin (1270.28 g/mol) with 400 mg fluconazole (306.27 g/mol) is equal to 0.039 mmol micafungin and 1.306 mmol fluconazole. The results of the study showed that the overall success rate in the micafungin arm was comparable to that of the fluconazole arm (94\% vs.
88%, respectively), which seems to suggest that micafungin could be treated as a new valuable option for antifungal prophylaxis.\textsuperscript{[160]} Although 50 mg of micafungin has been approved for IFI prophylaxis, a higher dose of micafungin (150 mg daily; 0.118 mmol) has been found to be significantly more effective in several trials (for the treatment of esophageal candidiasis; endoscopic cure rate: 89.8% vs. 68.8%, respectively).\textsuperscript{[161,162]} In addition to the antifungal prophylaxis, the efficacy of micafungin for the treatment of severe IC has been studied in a Phase III randomized, double-blind, multinational trial of over 500 adult patients to compare micafungin (100 mg/day) with L-AmB (3 mg/kg per day).\textsuperscript{[163]} Of 202 patients in the micafungin group, overall treatment success was seen in 181 patients (89.6%), which is comparable to the results in the L-AmB group with an overall success observed in 170 of 190 patients (89.5%).\textsuperscript{[163]} Meanwhile, fewer treatment-related adverse effects were found to be attributed to the use of micafungin than with L-AmB, which was consistent with reports about safety profiles from other reports.\textsuperscript{[163]} However, a different unit system (mg/day vs. mg/kg per day) was used for dosage in the study, which may lead to untenable conclusions due to the difference in molar weight between micafungin and AmB. Still, several comparative studies have indicated micafungin being equally efficacious, yet less toxic than AmB, despite AmB and L-AmB being considered as the standard EAT for fungal infections. Therefore, a recent
study was designed and performed to evaluate micafungin for EAT of febrile neutropenia in patients with hematological malignancies.\(^{164}\) Of 53 patients who received chemotherapy for hematological malignancies, and more than 72 hours of systemic antibacterial therapy while fever and neutropenia persisted, resolution of fever during neutropenia was achieved in 37 patients (70%) by taking micafungin (150 mg/day). All patients who were positive for BDG or *Aspergillus* became negative.\(^{164}\) According to the results, micafungin appears to be safe and effective as used in EAT for treating febrile neutropenia in hematologic malignancies.

Anidulafungin is the newest echinocandin approved in 2006 by the FDA to use in the treatment of oesophageal candidiasis, candidemia, peritonitis and intra-abdominal abscesses due to *Candida* spp. in this class.\(^{103}\) As mentioned earlier, anidulafungin is unique because it undergoes a process of non-enzymatic biotransformation for degradation rather than being metabolized via CYP450 enzymes. Consequently, anidulafungin is endowed with an outstanding advantage and it is not affected by concomitant treatment with substrates, inhibitors, or inducers of the CYP450.\(^{151,165}\) In addition, there is no need for dose adjustments for patients with any degree of renal or hepatic insufficiency for the use of anidulafungin.\(^{166,167}\) In a randomized double-blind trial comparing anidulafungin with fluconazole for treatment of IC, eligible patients (245 out of 261) were randomized to receive either intravenous anidulafungin
or intravenous fluconazole for 14-42 days. At the end of intravenous therapy, there was a significantly better global response rate with anidulafungin (75.6%) than with fluconazole (60.2%; P=0.01). Since *C. albicans* were isolated in 62% of the 245 patients as the major causative pathogen, it is noteworthy that the difference in the global response rates against *C. albicans* infections was evident between the two treatments (81.1% for anidulafungin vs. 62.3% for fluconazole, P=0.02).

It is well known that critically ill patients are the vulnerable population against nosocomial infections frequently caused by *Candida spp.* An echinocandin is recommended by the IDSA 2009 candidiasis guideline for the treatment of IC in patients who are considered to be “moderately severe or severely” ill. Therefore, a post hoc analysis was conducted to compare the responses to anidulafungin with fluconazole in this population. One hundred and sixty-three patients were identified from the original study that met at least one criterion for critical illness (89 in anidulafungin group, 74 in fluconazole group). Global responses at the end of therapy were more favorable with anidulafungin (70.8%) than with fluconazole (54.1%, P=0.03), which supported the 2009 IDSA guidelines for anidulafungin being more effective than fluconazole in treating critically ill patients with candidemia. Since anidulafungin has a broad spectrum of activity against *Candida* species, including strains resistant to azoles and AmB, an open-label, non-
A comparative small-scale trial was performed to evaluate efficacy of anidulafungin in patients with azole-refractory oropharyngeal and esophageal candidiasis. Nineteen patients, who had failed treatment of 14 days with either fluconazole or voriconazole, were enrolled in the study. At the end of the therapy, clinical success was observed in 18 of 19 patients (95%) and 11 of 12 patients (92%) were defined as endoscopic success. For the follow-up visit, the success rates were evaluated again, and 14 patients (47%) were found to remain successful, 10-14 days after end of therapy. Although this study was limited by the small sample size, it still provided some valuable information and suggested that anidulafungin could be an effective, well-tolerated treatment option for azole-refractory mucosal candidiasis.

Yet, there are not many studies that have been performed to evaluate the safety profiles of anidulafungin in the use of clinical settings, and adverse events were rarely reported so far. A recent study was conducted to evaluate the safety profile of anidulafungin in adult SOT recipients. Eighty-six SOT recipients from 14 centers were enrolled in this study over 14 months who received anidulafungin for at least 48 hours as the treatment of IFIs (24, 28%) or as prophylaxis (62, 72%). The results showed that anidulafungin was generally safe and well tolerated in SOT recipients and there was no patient discontinued from anidulafungin due to severe adverse effects. In particular, there was no case of hepatotoxicity.
or renal failure directly attributed to the use of anidulafungin and no need for modification of immunosuppressive drug doses due to anidulafungin therapy, which is important to SOT recipients. [171]

1.4 Antifungal strategies

Due to the limited diagnostic techniques that are currently available and the fact that many IFIs can only be detected at a relatively late stage, developing more effective antifungal strategies has been very important for the management of IFIs. To be a successful antifungal strategy, it should not only match the individual case with proper treatment and regimen, but also be able to balance efficacy and safety (to avoid overuse and underuse). There are four general strategies available now for the management of IFIs, including prophylaxis, EAT, preemptive antifungal therapy and targeted therapy (treatment of established IFI). The definition of each strategy is described in Table 1.1.

1.4.1 Antifungal prophylaxis

Before antifungal prophylaxis became widely used, about 20% of febrile neutropenic patients treated for acute leukemia or those undergoing HSCT had developed an IFI with Candida or Aspergillus species by day 20 of neutropenia. [172]
Table 1.1. Strategies for management of IFIs, modified from Segal B.H., et al. [13,173]

<table>
<thead>
<tr>
<th>Strategy</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prophylaxis</td>
<td>Antifungal agents are provided to patients at high risk of infection to prevent potential fungal infections</td>
</tr>
<tr>
<td>Empirical treatment</td>
<td>Treatment is initiated on an empirical basis in persistently febrile patients with neutropenia, which is without a known source and is not responding to adequate antibacterial therapy</td>
</tr>
<tr>
<td>Preemptive therapy</td>
<td>Although similar to empirical treatment to treat a suspected early IFI, preemptive therapy is usually based on clinical and/or laboratory findings suggesting IFI without microbiology identification</td>
</tr>
<tr>
<td>Targeted therapy</td>
<td>Targeted therapy is only used in patients with proven IFI based on pathogen identification and should be modified according to patient’s clinical presentation and previous antifungal therapy and prophylaxis</td>
</tr>
</tbody>
</table>

Due to the high mortality associated with IFIs in immunocompromised patients, antifungal prophylaxis has been recommended in selected high-risk patients. According to the recommendations of the ‘First European Conference of Infections in Leukaemia’ (ECIL 1) and the ‘Infectious Diseases Working Party of the German Society of Haematology and Oncology’, antifungal prophylaxis should be provided to patients with granulocytopenia (<500 cells µl⁻¹) for more than seven days and also in allogeneic HSCT recipients. [174,175] For prophylaxis to get so much attention, one of the clinical trials played a very important role in the process. Back in 1992, a randomized, placebo-controlled trial demonstrated the utility and benefits of using fluconazole.
Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents

for prophylaxis. In the study, unexplained fever was observed in many of the patients in both fluconazole (101 of 179) and placebo (116 of 177) arms and empirical AmB therapy was provided to patients with persistent fever. By analyzing the causes of fever in patients who received AmB therapy, IFIs occurred in 21 of 116 patients in placebo group, but in only 1 of 101 in fluconazole group (18.1% vs. 1%, P<0.001). In total, proven IFIs were present in 28 of 177 patients receiving placebo (15.8%), but in only 5 of the 179 patients receiving fluconazole (2.8%, P<0.001). The positive results not only placed the foundation of using fluconazole as antifungal prophylaxis, but also prompted intensive evaluation on fluconazole and other antifungal agents for prophylaxis in the following decades.

However, whether an antifungal should be recommended and how to select the correct population still remain controversial in practical use, because it may increase the medical expenses and also cause possible exposure to unnecessary drug-related toxicity and induction of drug-resistant fungal species. Due to all of these concerns, the target groups for prophylaxis should be defined strictly. Primary prophylaxis, which aims at truly preventing fungal infection in patients with no history of IFIs, should be clearly separated from secondary prophylaxis, which targets prevention of recurrence of IFIs for patients at high risk. Although fluconazole remains the most frequently prescribed agent for
prophylaxis, it lacks activity against moulds (e.g. *Aspergillus* spp.), and
also many different fungal species have shown drug-resistance (e.g. *C.
krusei*) or poor susceptibility (e.g. *C. glabrata*) towards fluconazole, which
significantly limits its use. [177] Along with the development of newer
antifungal agents and formulations with broader spectrum of activity, and
better pharmacokinetic and safety profiles, there are more and more
antifungal agents available for prophylaxis, such as L-AmB, posaconazole,
voriconazole or echinocandins. In order to find better alternatives to
fluconazole for antifungal prophylaxis, a large number of studies were
initiated that focused on comparison of different antifungal agents used
for prophylaxis. [158] The recommendations of antifungal prophylaxis using
a grading system were included in 2009 IDSA guidelines on the
management of candidiasis [20] and aspergillosis, [53] which includes
fluconazole, itraconazole, posaconazole, caspofungin and micafungin for
different populations.

1.4.2 EAT

Although not proven with enough evidence, EAT remains the
standard of care in patients with granulocytopenia and persistent or
recurrent fever of unknown causes despite treatment with broad-spectrum
antibiotics. [172] Two studies, which were conducted in the 1980s, showed
that a lower incidence of IFIs in antibiotic-treated neutropenic patients
with persistent fever was attributed to EAT with AmB.\textsuperscript{[178,179]} In the study with a larger sample size, the number of deaths from IFI was much lower in patients receiving empirical AmB compared with the control group (0 vs. 4; $P=0.05$).\textsuperscript{[178]} In the controlled study published in 1989, initiation of AmB after four days if antibiotics seemed ineffective was compared with continuation of antibiotics. The result suggested a decrease in breakthrough fungal infections during and after therapy and also an overall better response (defervescence).\textsuperscript{[179]} Since then, 40-50\% of high-risk neutropenic patients received EAT without requiring any microbiological or radiological documentation of IFIs.\textsuperscript{[180]} The rationale for the use of EAT is also supported by the evidence from previous studies indicating that withholding antifungal treatment until getting a conclusive diagnosis frequently leads to disseminated infection with high mortality.\textsuperscript{[177]} Due to the lack of pathogen identification, the clinician has to select an EAT regimen covering the most likely causative pathogens based on local epidemiology and clinical presentations and symptoms.\textsuperscript{[181]} A study in clinical practices showed that the choice of EAT regimen is also influenced by the previously used antifungal prophylaxis, in which case the clinician will want to avoid an antifungal agent from the same class as prophylaxis, due to the concern of cross-resistance.\textsuperscript{[182]}

In recent years, EAT has been increasingly questioned, because the two historical studies supporting this approach are not convincing due to
the small sample size and questionable methodology that only compared AmB with placebo without showing significant effectiveness in reducing IFI incidence or mortality. \cite{178,179} Moreover, when it comes to the entry point for initiation of EAT, it is also not well accepted. Although fever in neutropenic patients should be given attention and trigger further tests and evaluation, the appropriateness of using fever alone as a specific criterion for initiation of EAT has been widely debated, since there are many origins of fever in neutropenic patients. \cite{173,182,183} In addition, at the time the trials were conducted, there were few diagnostic techniques available to provide early diagnosis for IFIs. \cite{184} The development in antifungal agents and improvements in the treatment and clinical management of IFIs are significant over the years, which makes it difficult and untenable to draw comparison between the results of historic trials and current practices. \cite{184} On the other hand, the cost of antifungals has a significant impact on the overall antimicrobial budget. Although the published data about antifungal consumption and cost-effectiveness are limited, it can still be inferred from the studies that the majority of antifungal budget was spent on antifungal prophylaxis and even more on EAT. \cite{185} In a seven-year antimicrobial stewardship program conducted by a large tertiary hospital, data indicated that the average antifungal cost represented 29.5% of the overall antimicrobial expenditure ranging from 47.7% ($3.7 million) to 18.8% ($1.2 million) before and after the program
implementation, which lays the emphasis on management and appropriate indications for EAT. [186]

Following the two historic studies of EAT, in which there was a control group who received no antifungal treatment, all subsequent trials have used different classes of antifungal agents as comparators, including various doses or formulations of AmB, azoles and also echinocandins to identify the most appropriate agent for EAT. [80,172] Nevertheless, all clinical trials of EAT performed during the last two decades have neither revealed a distinct superior antifungal agent with regard to efficacy, even with substantially larger sample sizes, nor indicated expected reduction in IFI incidence or IFI related mortality associated with EAT. [172,185] Moreover, as IFI symptoms are usually unspecific, EAT brings similar risks as antifungal prophylaxis, namely exposure of the patients without IFI to unnecessary drug-related toxicity and increased costs and also possible induction of antifungal resistance.

Although EAT of suspected fungal infections may not be the ideal approach to deal with the increasing incidence of IFIs, it has been well-accepted as a standard therapy, since delayed treatment will clearly lead to increased morbidity and mortality. Without better diagnostic methods and novel antifungal agents, EAT will remain as a very important antifungal therapy, especially for patients at high risk. Overall, EAT remains the standard approach for management of presumed IFIs.
allowing early exposure of fungal pathogens to adequate proper treatments and also helps to avoid the high mortality associated with various fungal species, limited early diagnostic methods and undetected infections. [172]

1.4.3 Preemptive therapy

It is known that establishing a definitive diagnosis of IFI is difficult and time-consuming, because the symptoms are usually nonspecific and may not be present until very late stages of diseases. [72] With improved non-invasive diagnostic methods, advanced radiological tests and better understanding of the pathogenesis of fungal infections, new approaches should be proposed to restrict the administration of antifungal agents to patients without any evidence from diagnostic tests. The preemptive approach is based on the combination of clinical and laboratory findings suggesting early IFIs before the development of clinically overt disease, without pathogen identification. The original intentions of proposing preemptive approach included avoiding the unnecessary use of antifungal agents, as well as drug-related toxicities in patients with non-fungal caused fever. [173] Preemptive therapy is a newer and evolving approach for the management of IFIs that has been receiving increasing attention, but it is still at an exploratory level and does not have standardized criteria. [181] Due to the lack of standardization, various diagnostic
techniques are adopted in different approaches, mainly focused on high-incidence infections, namely IA and IC. By using GM screening, BDG assay and CT scans, the common goal is to be more selective towards patients at risk of IFIs and decreased toxicity, costs and risk of emerging resistance. However, use of different diagnostic methods, criteria used for initiating antifungal treatment and enrolling patients have caused tremendous difficulties in comparing the limited existing trials regarding preemptive therapy.

Amongst all of the techniques adopted in the diagnosis of IFIs, radiology, particularly CT, plays a very important role. The typical radiological ‘halo’ or ‘air-crescent’ sign of an IA, which can be better observed by HRCT, is defined and allowed to support the diagnosis of probable or possible fungal infections according to EORTC/MSG criteria, even though the sign is not entirely specific for fungal infections. Moreover, preemptive therapy is also guided by biomarker detection, including GM ELISA and BDG assays. Additionally, direct microscopy and culture-based tests are suggested on BAL fluid in patients with pulmonary infiltrates. The combination of sequential monitoring of GM with HRCT was reported to reduce antifungal use by 78% (from 35% to 7.7%) when compared with fever-driven EAT in a prospective feasibility non-randomized study. This study has also opened up new ways forward for similar algorithm incorporating non-culture-based
microbiological techniques with the use of HRCT to become well-accepted by many other clinical trials.\textsuperscript{[188]} However, there is no consensus on recommendations for variables in GM assay that can have a great impact on the performance, including GM index cutoff level (varying from 0.5 to 1.0), test interval and required number of positive samples.\textsuperscript{[13,177,188]} Generally, a GM assay should be carried out at least twice per week when the cutoff for positivity is 0.5 and two consecutive positive samples are required, while HRCT of the chest is suggested to be performed at least every 7-10 days.\textsuperscript{[187,188]}

Although only limited data have been published comparing a preemptive with an empirical strategy, an open-label, randomized, controlled trial of empirical versus preemptive therapy in high-risk patients due to chemotherapy or HSCT has reported similar survival rates with both arms.\textsuperscript{[184]} All patients were screened twice weekly by GM ELISA with the GM index $\geq 1.5$ adopted as a cutoff level and chest radiograph together with CT as further confirmation in the group of preemptive therapy.\textsuperscript{[184]} AmB or L-AmB, depending on patient’s renal function, was used as antifungal treatment in both groups. It was shown that there was no significant difference in overall survival between the two strategies (preemptive 95.1% vs. EAT 97.3%).\textsuperscript{[184]} However, the incidence of IFI was significantly higher in the preemptive group than that in the EAT group (9.1% vs. 2.7%, respectively), so that the use of
antifungal agents was much lower in the preemptive arm (1 out of 56 treated patients, 1.8%) compared with EAT arm (55 out of 92 treated patients, 59.8%, P<0.001). Instead of using the combination of chest CT and non-culture laboratory findings as diagnostic methods, clinical symptoms were adopted in this study as criteria for preemptive therapy. Still, the results have shown that preemptive therapy was more selective towards patients at-risk, so that antifungal consumption decreased without increasing mortality. With all of the uncertainty and questions, more research is needed to get preemptive therapy standardized and to compare preemptive with EAT strategies. Further studies are also required to investigate which diagnostic method, biomarker or clinical finding or both, should be dominant to guide preemptive therapy.

1.4.4 Targeted therapy

As mentioned earlier, the classification of IFIs is based on the degree of diagnostic certainty, including proven, probable and possible IFIs. The reason for setting these strict diagnostic criteria of IFIs is to help standardize the target groups of patients in the clinical routine and studies. Yet, these criteria may not intend to guide therapeutic decisions in individual patients due to their limited flexibility and applicability. Although an increasing number of new technologies have become available as diagnostic methods, the definite diagnosis of IFI still can only
be obtained by sterile conditions (e.g. blood-cultures) and/or tissue specimens for histological tests, according to the criteria. However, the microbiological and histological detection of fungi is often associated with many problems, such as being time-consuming and relatively insensitive, also being too invasive to conduct, particularly on the deep-seated infection sites. \[13,21,24\] The term “targeted therapy”, also known as treatment of established IFIs, is used for the treatment of patients with proven IFIs based on the pathogen identification achieved via microbiological and histopathological examinations. \[13,173\] Due to the known limitations of conventional diagnostic techniques, especially the risk coming along with invasive diagnostic procedures, targeted therapy is not always achievable or suitable for patients in different conditions. \[177\] Therefore, the first step before providing targeted therapy is elaborate evaluation of clinical presentations, risk factors that may lead to the emergence of IFI and previous antifungal treatment and prophylaxis. \[177\]

There have been many studies and guidelines with regard to targeted therapy in IFIs, especially in IC and IA, which aim at studying not only the effectiveness of the strategy itself, but also comparing various antifungal agents for different indications. \[20,189,190,191,192\] With regard to targeted therapy in IC, international guidelines recommend several agents for primary and second-line treatment for IC depending on the patient’s conditions, previous use of antifungal agents and local epidemiology. \[185\]
For non-neutropenic patients, fluconazole or an echinocandin is recommended as primary therapy in most international guidelines, and AmB is suggested as an alternative in case of intolerance.\textsuperscript{20,189} Recently, the use of an echinocandin as first-line treatment of IC in non-neutropenic patients has become increasingly popular considering the risk of azole-resistant \textit{Candida spp.} strains, while more clinical trials are still needed to support this recommendation.\textsuperscript{185} For neutropenic patients, caspofungin or micafungin is preferred as primary antifungal therapy and L-AmB remains a second-line treatment.\textsuperscript{193} On the other hand, voriconazole is considered the agent of choice for first-line therapy in IA and L-AmB may be used as an alternative therapy with similar efficacy but higher toxicity.\textsuperscript{177} Regardless of which drug is selected for targeted therapy, the regimen should be adjusted to fit the patient’s situation according to clinical presentation, concomitant medication and risk of resistance.

1.4.5 Combination therapy

In order to fight against the high mortality and poor prognosis associated with IFIs, IA in particular, combination therapy tends to draw attention from clinicians as a salvage therapy based on the clinical situation.\textsuperscript{13} Echinocandins have contributed to combination therapy and become even more attractive, since the new class of antifungal agents exhibits a distinctive mechanism of action. However, the benefits of
combination therapy are still controversial as a result of insufficient clinical trials, even though combination therapy is already recommended in the IDSA guidelines for second-line (salvage) therapy. The basis of using combination therapy are the improvements in outcomes observed from a few *in vitro* and animal studies that indicated synergistic, or at least additive, effects when an echinocandin was added in the use of a mold-active triazole or AmB. In the most recent review, a meta-analysis was performed to compare mold-active triazoles or L-AmB plus an echinocandin to non-echinocandin monotherapy for acute IA. The results did confirm that certain themes of combination therapy could lead to significantly improved 12-week survival and composite success over monotherapy in salvage setting of IA. Nevertheless, routine use of combination therapy for initial target IA treatment is not well-supported. Both the recent meta-analysis and a previous critical review have come to the same conclusion in which the cumulative evidence is not strong enough to support combination therapy as a routine primary treatment for IA, while some favorable effects were reported as salvage therapy. By combining antifungal agents with different modes of action, combination therapy may be useful before the IA species is specified. Given the heterogeneity of the regimens, patient populations, primary and secondary endpoints in the limited number of existing studies, more well-
designed controlled, randomized, multicenter clinical trials are required to allow well-grounded conclusions on the usefulness of this approach. \[196,197\]

1.5 Rationale of the project

Since the late 1970s, inhibitors of fungal cell wall biosynthesis have gained great attention all over the world as a new direction of drug design for the treatment of IFIs because of their distinct mode of action. So far, glucan synthesis remains the only component of cell wall synthesis for the development of antifungal agents with BDG as the drug target in particular. Echinocandin B 5 (Figure 1.6), one of the cyclic lipopeptides in this class, was reported in 1974. \[142\] Later on, efforts in natural product screening led to the discovery of the pneumocandin series. In 1987, pneumocandin A\(_0\) 5a was isolated and its structure was then determined. Its antifungal activity was shown to be achieved by inhibiting the synthesis of the fungal cell wall, via inhibition of BDG synthase. \[198\]

Right after the study of pneumocandin A\(_0\), pneumocandin B\(_0\) 5b was isolated and characterized as the desmethyl congener. \[198\] Pneumocandin B\(_0\) became the key for further development of BDG inhibitors. \[141,199\]

Pneumocandins that mainly include pneumocandin A\(_0\) 5a, pneumocandin B\(_0\) 5b and pneumocandin C\(_0\) 5c, are derived from fermentation of fungus Glarea lozoyensis (originally called Zalerion arboricola). \[200,201\] The
structures of echinocandin B 5 and the three pneumocandins are illustrated in Figure 1.8.

Nevertheless, the research on pneumocandin A₀ and B₀ was not completed due to a shortage of material and the fact that the pneumocandin A₀ lead had been lost owing to its poor oral bioavailability, water solubility and a lack of broad antifungal spectrum, as well as discovery of its semisynthetic analog, cilofungin 5d (Figure 1.8). The clinical trial for cilofungin was actually halted in 1988, owing to the toxicity of a co-solvent used for oral administration, which led the focus of research back to pneumocandin A₀ and B₀. Later that year, based on findings of DNA studies, it was suggested that *Pneumocystis* was a fungus rather than a protozoan (the pathogen in humans is *P. jiroveci*). It is worth noting that the wall of the cyst form of *P. jiroveci* was reported to contain high levels of BDG. With all the information together, the program of pneumocandin A₀ and B₀ was reinvigorated in 1989 with a test in an immunosuppressed rat model of *P. carinii* pneumonia using pneumocandin A₀. Subsequently, pneumocandin B₀ became the lead compound in a medicinal chemistry program for further development. In order to improve the solubility, stability, antifungal spectrum and pharmacokinetic profiles, semisynthetic optimization of pneumocandin B₀ has been explored.
Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents

Figure 1.8. Structures of echinocandin B 5, pneumocandin A₀ 5a, B₀ 5b and C₀ 5c, and cilofungin 5d.
Among the three members in the class of echinocandins described earlier, caspofungin (MK-0991) and micafungin (FK-463) are pneumocandin B<sub>0</sub> analogues and anidulafungin was derived from echinocandin B. The semisynthetic nature of echinocandins not only demands procedures like fermentation, isolation and purification, but also brings additional cost, making echinocandins more expensive than other classes of antifungal agents. Another limitation that comes along with echinocandins is their poor oral bioavailability, which makes them only available for intravenous use. Considering the broad antifungal spectrum, outstanding safety properties, potential in combination therapy and also the limitations of the current echinocandins, efforts were made to design peptidomimetic analogues of echinocandin B that can be fully synthesized and are smaller molecules.

The target for echinocandins is the protein complex responsible for the synthesis of one of the essential fungal cell wall components, BDG polysaccharides. The enzyme complex has been extensively studied in \textit{S. cerevisiae} and Fks1p, Fks2p and Rho1p are indicated to be subunits of the complex. Among the three fractions, Fks1p is thought to be the target and binding site of echinocandins and may also be the catalytic center of BDG synthase. Meanwhile, both Fks1p and Fks2p are regulated by elements of the calcineurin pathway, and by Rho1p, a GTP-binding peptide, which also interacts with protein kinase C. Given the
possible interaction of echinocandins with the catalytic component of BDG synthase to achieve the inhibition of enzymatic activity, it was intended to use smaller linear or cyclic peptidomimetic molecules to mimic the backbone of echinocandins.\textsuperscript{202} However, it turned out that the lipophilic side chain and the homotyrosine moiety of echinocandin are essential for their antifungal activity.\textsuperscript{202,204,205} Even the relative orientation of the homotyrosine ring with the lipophilic side chain may have a significant impact on the activity of echinocandins as well.\textsuperscript{202}

By adopting computer-aided drug design, a series of structurally related natural and synthetic analogues of homotyrosine were examined by Daneshtalab\textsuperscript{202} by overlapping with echinocandin B. It was found that chlorogenic acid (CGA) \textbf{10} with a \textit{para-}alkoxyphenylamido side-chain (CGA derivative \textbf{11}) was the best match and it has the most favorable spatial relationship of the essential groups with those of echinocandin B.\textsuperscript{206} As a natural product, CGA exists widely in many vegetables and plants, and is known as an antioxidant.\textsuperscript{202,206} Being an ester of caffeic acid and quinic acid, CGA can be considered as a bioisostere of homotyrosine-hydroxyproline, which is very similar to a part of echinocandin B, as shown in Figure 1.9. Hence, with lipophilic side chains, CGA derivatives could be potentially useful bioisosteric replacements for the particular part of echinocandin B, and could possess potential useful antifungal activity.\textsuperscript{202,206}
Figure 1.9. Structures of echinocandin B 5, CGA 10 and its derivatives 11 and 12l (see Scheme 1.1).
Therefore, a series of CGA derivatives (Scheme 1.1) were synthesized and their activities were assessed. Their in vitro BDG synthase inhibitory activities were compared with that of aculeacin A 6 (Figure 1.6), which is also, like echinocandin B, a prototype inhibitor of BDG synthase. [206,207] Results expressed as IC₅₀ values represent the concentrations that inhibit 50% of the enzyme activity. [207] When CGA was modified to form the octyloxyanilido derivative having a long alkyl chain to afford CGA derivative 11 (Figure 1.9), its IC₅₀ was 23 µg/ml, which is better than that of CGA (>32 µg/ml), but still much higher than that of aculeacin A (9 µg/ml). [207]

In order to improve the enzymatic inhibitory activity, further structural modifications were conducted with the incorporation of different amino acids into the structure of CGA. [207] The synthetic routes for the preparation of these CGA derivatives 12a-l are shown in Scheme 1.1, in which the p-octyloxyaniline was modified with the various protected amino acids.

Among these compounds, CGA derivative 12l showed the best activity with an IC₅₀ value of 10 µg/ml, which is very close to that of the positive control compound (aculeacin A). [206,207] The specific structure of CGA derivative 12l is illustrated in Figure 1.9. It was found that the incorporation of ornithine in CGA derivative 12l resulted in greater overlap with echinocandin B than the previous molecules studied.
Scheme 1.1. Synthesis of CGA derivatives 12a-l

Reagents and conditions: (i) CMC, HOBT; (ii) acetone-H_2O, 0.67 M HCl, rt, 1h; (iii) 90% TFA, rt, 30 min. [206]
The comparison between the overlap of 11 and 5 and that of 12l and 5 is shown in Figure 1.10.

As illustrated in Figure 1.11 (a), CGA derivative 12l can be divided into various sections, including the octyloxyaniline grouping with a lipophilic side chain, the ornithine, the quinic acid and caffeic acid. Although proven to have a good enzymatic inhibitory activity in vitro, subsequent findings regarding CGA derivative 12l showed that the ester bond could be easily broken in vivo during metabolism and the quinic acid derivative part would be released into the blood as shown in Figure 1.11 (b). \(^\text{[207]}\)
Consequently, it became important to investigate if the quinic acid derivative 14b was active. If so, the CGA derivatives could still be developed as parent drugs. Subsequently, quinic acid derivatives 14a-e were synthesized as shown in Scheme 1.2 and their in vitro activity was evaluated. It was found that quinic acid derivative 14b was the most active of the quinic acid derivatives, with an IC<sub>50</sub> of 27 µg/ml. However, it is not as active as CGA derivative 12l (10 µg/ml). [207]
Scheme 1.2. Synthesis of quinic acid derivatives 14a-e\([^{207}]\).
Due to the reactivity of the ester bond in CGA derivative 12l and the hydrolytic product, quinic acid derivative 14b, is not as active as CGA derivative 12l. It was therefore considered necessary to remove the quinic acid section from the CGA derivatives in order to improve their stability and activity. In accordance with the above hypothesis, synthesis of the derivative 16g of caffeic acid 15 as shown in Figure 1.12 was then pursued.

Since there is no ester bond in the structure of the targeted caffeic acid derivatives, a better stability was expected. Hence, a series of caffeic acid derivatives (16a-i) were synthesized as shown in Scheme 1.4, and their BDG synthase inhibitory activities and stabilities were assessed. It was found that the activity of caffeic acid derivative 16g (11 µg/ml) was similar to that of CGA derivative 12l, yet better than that of the quinic acid derivative 14b.
Scheme 1.3. Synthesis of caffeic acid derivatives 16a-i [207]
Table 1.2 is a summary of the bioassay results of CGA and its derivative, caffeic and quinic acid derivatives. A more recent follow-up study investigated the metabolism of CGA derivative 12l, quinic acid BDG synthase inhibitory activity and antifungal activity.

<table>
<thead>
<tr>
<th>Compound</th>
<th>BDG synthase inhibitory activity</th>
<th>In vitro antifungal activity</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IC&lt;sub&gt;50&lt;/sub&gt;* (µg/ml)</td>
<td>MIC** (µg/ml)</td>
</tr>
<tr>
<td>Caffeic acid derivative 16d</td>
<td>31</td>
<td>16</td>
</tr>
<tr>
<td>Caffeic acid derivative 16g</td>
<td>11</td>
<td>2</td>
</tr>
<tr>
<td>Quinic acid derivative 14b</td>
<td>27</td>
<td>8</td>
</tr>
<tr>
<td>Chlorogenic acid derivative 12l</td>
<td>10</td>
<td>4</td>
</tr>
<tr>
<td>Chlorogenic acid 10</td>
<td>&gt;32</td>
<td>&gt;64</td>
</tr>
<tr>
<td>Aculeacin A 6</td>
<td>9</td>
<td>0.25</td>
</tr>
</tbody>
</table>

Table 1.2. BDG synthase inhibitory and antifungal activities

*IC<sub>50</sub>: the concentration needed to inhibit a biological or biochemical function by half.

**MIC: the lowest concentration of an antimicrobial that will inhibit the visible growth of a microorganism after overnight incubation.

Table 1.2 is a summary of the bioassay results of CGA and its derivative 12l, caffeic and quinic acid derivatives. A more recent follow-up study investigated the metabolism of CGA derivative 12l, quinic acid BDG synthase inhibitory activity and antifungal activity.
derivative 14b, and caffeic acid derivative 16g conjugated with an H$_2$N-Orn-4-octyloxyaniline in rats after oral and intravenous administration using ultra-performance liquid chromatography–atmospheric-pressure-chemical ionization–tandem mass spectrometry (UPLC-APCI-MS/MS) with negative ion polarity mode. The metabolic pathway in rats for chlorogenic, quinic and caffeic acid derivatives inferred from molecular fragments detected by MS is believed to be as shown in Scheme 1.4. The results in that study, not only revealed the metabolic pathway of those compounds in a rat model, but also pointed out a critical problem. After CGA derivative 12l was administered orally or intravenously to rats, caffeic acid was detected in the plasma samples, which verified that the ester bond linked to caffeic acid in the CGA derivative 12l did break to release quinic acid derivative and caffeic acid into the systemic circulation. In the case of caffeic acid derivative 16g, the parent compound was detected in the plasma sample after intravenous administration. However, from 15 min to 4h following oral administration, both the substrate (the molecule after a loss of proton, m/z 496 [M-H]$^-$) of caffeic acid derivative 16g ($M_w=497.29$) and caffeic acid were detected in the plasma samples. Therefore, it was found that the caffeic acid fraction in the caffeic acid derivative also had a tendency to dissociate. Specifically, no caffeic acid or the substrate was found in the plasma samples collected at 30 min, 1 h and 1.5 h after oral administration of
caffeic acid derivative 16g. However, 2 h after oral dose, both caffeic and isomerized caffeic acid derivative 16g were detected in plasma sample, which indicated that caffeic acid derivative 16g could take part in the systemic circulation while only for a limited time and amount. \[208\] Comparing the metabolic profiles of CGA derivative 12l with caffeic acid derivative 16g, the results are consistent with the well-accepted theory that amides are more stable than esters, though still less than ideal. \[208\]

As the metabolites of caffeic acid derivative 16g were found to be inactive in vivo, it was necessary to re-examine the structure of caffeic acid derivative 16g seeking ideas to improve the stability. In the structure of caffeic acid derivative 16g, there is a double bond located next to the amide bond, which constitutes a conjugation system that might result in increasing reactivity of the amide bond. Due to keto-enol tautomerization, the amide bonds are endowed with partial-double bond character, which is stabilizing. With tautomerization, the nitrogen is enabled to donate its lone pair of electrons to the carbonyl carbon and push electrons from the carbonyl double bond towards the oxygen, forming the oxygen anion. By delocalizing the electrons over several atoms, the double bond resonance form of the peptide bond helps to increase stability and decrease rotation about that bond as shown in Figure 1.13.

On the other hand, either resonance form of the amide bond in caffeic acid derivative 16g (-C=N or -C=O double bond) could form a conjugated
system with the double bond beside it, which has a region of overlapping
\( p \)-orbitals, bridging the interjacent single bond that allows electrons
delocalized across all of the adjacent aligned \( p \)-orbitals. Although a
conjugated system originally may lower the overall energy of the
molecule and increase stability, conjugation with a resonance form of
amide bond could actually weaken the resonance that was playing the
most important role to stabilize the amide bond resulting in increased
amide reactivity. Therefore, further structural modification on caffeic acid
derivative \textbf{16g} to remove the double bond next to the amide bond should
be conducted to prepare a more stable molecule. As a result, a new
molecule, a dihydrocaffeic acid (i.e. 3,4-dihydroxyhydrocinnamic acid)
derivative, became one of the target compounds in this project, aiming at
better stability. Its synthesis is described in section 3.2.4.

Figure 1.13. Resonance structures of amide bond (with and without
double bond)
Scheme 1.4. The deduced metabolic scheme for CGA derivative 12l, quinic acid derivative 14b, and caffeic acid derivative 16g, in rats. [208]
Chapter 2. Objectives

The objectives of this research project conducted by this author were as follows:

1. To repeat and refine previously synthesized caffeic acid derivative 16g.
2. To synthesize and characterize novel caffeic acid derivatives of improved stability.
3. To evaluate the novel caffeic acid derivative synthesized.

The work described in this thesis is a part of a larger overall project and was based on previous findings, which has been conducted in our research group. The main compounds of this project were caffeic acid derivative 16g and dihydrocaffeic acid derivative 20c as shown in Figure 2.1.

Although the synthesis and metabolism of caffeic acid derivative 16g had been previously reported, it was still necessary to repeat and optimize some of the synthetic details and to design better compounds. The aims of optimization were not only to improve the yield and purity of the product, but also to achieve higher efficiency and simplification.

Caffeic acid derivative 16g was synthesized according to the method that was previously reported, [207] but with efforts made to improve it. After several attempts of using different reaction conditions and methods
to substitute the original operations, some techniques were verified to be effective in improving yield, purity and efficiency. Including inert gas (argon, nitrogen) protection to reactions, adopting longer reaction times and performing purification steps for final products were included in the optimizations undertaken.

[Chemical structures of caffeic acid and dihydrocaffeic acid derivatives]

Caffeic acid derivative 16g      Dihydrocaffeic acid derivative 20c

Figure 2.1. Structures of caffeic acid derivative 16g and dihydrocaffeic acid derivative 20c

In order to characterize both caffeic acid derivative 16g and dihydrocaffeic acid derivative 20c, infrared (IR) vibrational spectroscopy, liquid chromatography-mass spectrometry (LC-MS) and nuclear magnetic resonance (NMR) spectroscopy were used to identify molecules by analysis of their constituent bonds, functional groups, determining elemental composition and providing structural and dynamic information to elucidate the chemical structures of these products.
Chapter 3. Materials and Methods

3.1 Materials

The glassware used for all of the experiments were dried overnight in an oven (100°C). Most of the reactions were carried out under argon atmosphere unless aqueous solutions were involved. The low temperature (below 0°C) required in some of the reactions was obtained by using an ice-salt bath, where sodium chloride (NaCl) or calcium chloride (CaCl₂) was used. A thermometer was used to check the inner temperature of the reaction mixture, making sure that it reached the desired temperature. The reaction flask was usually stirred and heated on an adjustable dual-purpose magnetic stirrer-hot plate.

Extractions of products were conducted with organic solvents followed by a drying process using anhydrous sodium sulfate (Na₂SO₄), filtering through a glass funnel with a filter paper (qualitative filter paper for technical use, medium speed) and concentrated to dryness under reduced pressure with a rotary evaporator.

Thin layer chromatography (TLC) was performed using pre-coated aluminium sheets with 0.20 mm silica gel 60 with fluorescent indicator UV₂₅₄ (Fisher Chemical Company) to monitor the reaction progress, identify compounds present in a given mixture, and determine the purity of a substance. Caffeic and dihydrocaffeic derivatives with protecting
groups on the functional groups were examined under ultraviolet (UV) light, and unprotected derivatives were located by exposure to iodine vapor. Silica gel (60-200µm, 70-230 mesh) was used for column chromatography for isolation and purification. Due to the relatively high polarity of the compounds in this project, reversed-phase chromatography was necessary, where an octadecyl-functionalized silica gel (ODS) (200-400 mesh, Sigma-Aldrich, Inc.) was used.

**Reagents:**

Caffeic acid, 4-octyloxyaniline, 4-dimethylamino pyridine (DMAP), N,N-dimethylformamide (DMF) and all other reagents used were purchased from Sigma-Aldrich, Inc. and Tokyo Chemical Industry (TCI) Co., Ltd. The reagents that were involved in the experiments were either of American Chemical Society (ACS) reagents grade, high-performance liquid chromatography (HPLC) grade or anhydrous (99.8%). All reagents were used without further purification unless otherwise specified.

**Solvents:**

All solvents used in this research (except LC-MS and NMR analyses) were purchased from Caledon Laboratories Ltd., which were all reagent grade and tested by gas chromatography (GC) to be at least 99.5% in purity to meet the ACS specifications. All solvents used for LC-MS
analyses were of HPLC grade. The solvents used for NMR analyses included chloroform-\(d\) (CDCl\(_3\)) and methanol-\(d_4\) (CD\(_3\)OD), which were all deuterated solvents with the isotopic purity of 99.96 atom% D containing 0.03% (v/v) tetramethylsilane (TMS) as internal standard for calibrating chemical shifts.

**NMR Spectroscopy:**

Proton nuclear magnetic resonance spectra (\(^1\)H NMR) were determined at 300 MHz on a Bruker AVANCE III 300 instrument and CDCl\(_3\) and/or CD\(_3\)OD were used as solvent to dissolve the sample. \(^1\)H shifts were referenced to residual CDCl\(_3\) (\(\delta=7.26\)). The signal splitting patterns were represented as follows: “s” for singlet, “d” for doublet, “t” for triplet, “q” for quartet and “m” for multiplet.

**IR Spectroscopy:**

The IR spectra of solid substances were conducted on a Bruker Tensor 27 FT-IR spectrometer, which allows for direct analysis of solids, liquids and powders. The results were measured in transmittance mode that is suitable even for very thin specimens. The IR spectra are very useful in identification of functional groups of molecules, which can be particularly used in verification of whether the deprotection step was successful or not.
LC-MS:

The mass spectra were obtained using a LC/MSD (Trap) Agilent 1100 series SL with HPLC (1100 series) interfaced to an ion trap mass analyzer (model G2445D SL). Specifically, the HPLC is equipped with a vacuum degasser, quaternary pump, thermostatted auto sampler and UV-VIS diode array detector (wavelength range 190-900 nm), so that the data of UV absorption could be collected simultaneously. In addition, the mass spectrometry has two methods of ionization, electrospray (ESI) and atmospheric pressure chemical ionization (APCI), which can produce both monocharged and multiply-charged ions owing to the distinct mechanisms of ionization. Besides the MS mode, the LC/MSD (Trap) also has scan and multiple ion monitoring modes. Any one of the modes listed can be run in positive, negative or alternating polarity for ion detection.

3.2 Chemical synthesis

3.2.1 Synthesis of 3,4-diacetoxycinnamoyl chloride 15a

The acylation of caffeic acid 15 with acetic anhydride (≥99.5%) (Ac₂O) in pyridine to form 15b, followed by chlorination with two equivalents of oxalyl chloride provided 3,4-diacetoxycinnamoyl chloride 15a as shown in Scheme 3.1.
Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents

Following acetylation, extraction using ethyl acetate was performed to separate 15b from the aqueous reaction solution, followed by drying over anhydrous Na$_2$SO$_4$, filtering and evaporating to dryness on a rotary evaporator. The subsequent reaction involved using the moisture sensitive oxalyl chloride ((COCl)$_2$) to form 15a, which was used as shown in Scheme 1.3.

3.2.2 Synthesis of H$_2$N-Orn(Boc)-octyloxyaniline 13a

![Scheme 3.1. Synthesis of 3,4-diacetoxycinnamoyl chloride 15a.](image)

![Figure 3.1. Structure of 2-(((9H-fluoren-9-yl)methoxy)carboyl)amino)-5(((tert-butoxycarbonyl)amino)pentanoic acid (Fmoc-Orn(Boc)-OH) 17.](image)
The Fmoc-protected amino acid ornithine, Fmoc-Orn(Boc)-OH 17 (Figure 3.1), was condensed with 4-octyloxyaniline 18 in the presence of 1-cyclohexyl-3-(2-morpholinoethyl) carbo-diimidemetho-\(p\)-toluenesulfonate (CMC, Figure 3.2) and hydroxybenzotriazole (HOBr) to obtain the amino acid derivative 13d with the \(O\)-octyl lipophilic chain (Scheme 3.2).

The fluorenylmethyloxycarbonyl (Fmoc) and \textit{tert}-butoxycarbonyl (Boc) groups were used as the protecting groups for the two amino groups in ornithine (Figure 3.1). CMC, used in this reaction, is a water-soluble condensing reagent for peptide synthesis.

Figure 3.2. Structure of CMC
Before conducting the subsequent reactions, the product 13d was purified from the reaction mixture by using regular silica gel column chromatography and reversed-phase column chromatography with ODS gel according to the previous findings.\textsuperscript{[206]} Alternatively, another method can be used to replace the ODS column chromatography by adopting a series of washing steps to eliminate polar impurities. The compound was then treated with diethylamine (Et\textsubscript{2}NH) for removal of the Fmoc group, to produce the product 13a with the free secondary amino group.

3.2.3 Synthesis of caffeic acid derivative 16g

![Scheme 3.3. Synthesis of caffeic acid derivative 16g.](image)
With the two compounds (3,4-diacetoxyccinnamoyl chloride 15a and H$_2$N-Orn(Boc)-octyloxyaniline 13a) generated above, caffeic acid derivative 16g with protecting groups was obtained by coupling the two reactants with DMAP in pyridine (Scheme 3.3). The addition of pyridine not only provides basic conditions for the coupling reaction to occur and for the removal of generated HCl, but also helps to activate the carboxylic acid halides. The product of the coupling procedure was separated from the reaction mixture through extraction with dichloromethane (CH$_2$Cl$_2$) followed by purification using regular silica gel column chromatography before conducting the deprotection steps.

The deacetylation of 16a to form 16d was achieved with aqueous potassium hydroxide (KOH). The removal of the Boc group from 16d was accomplished with trifluoroacetic acid (TFA) in CH$_2$Cl$_2$ to afford the product 16g as the TFA salt. The mechanism of Boc deprotection with TFA is demonstrated in Scheme 3.4.

Scheme 3.4. Mechanism of Boc deprotection
In order to obtain caffeic acid derivative 16g with a free primary amino group, the TFA salt prepared above was extracted using ethyl acetate following treatment with aqueous saturated sodium bicarbonate (NaHCO₃).

3.2.4 Synthesis of 3,4-diacetoxydihydro-caffeoyl chloride 19b

Instead of caffeic acid, 3,4-dihydroxyhydrocinnamic acid 19 is used as the starting material in this reaction. It was dissolved in pyridine, and then treated with Ac₂O at 0°C in the presence of DMAP to afford the 3,4-diacetoxydihydro-caffeoyl acid 19a. Oxalyl chloride was then added to the solution of the product of acetylation in toluene with DMF to form product 19b.

3.2.5 Synthesis of dihydrocaffeic acid derivative 20c

To prepare the dihydrocaffeic acid derivative 20c, 3,4-diacetoxydihydro-caffeoyl chloride 19b was allowed to react with previously synthesized H₂N-Orn(Boc)-octyloxyaniline 13a in the presence of pyridine and DMAP to afford the dihydrocaffeic acid derivative 20a.
with protecting groups, as shown in Scheme 3.6. The aqueous phase was separated from the reaction mixture and re-extracted with CH₂Cl₂.

![Scheme 3.6. Synthesis of dihydrocaffeic acid derivative 20c](image)

The combined organic extracts were purified by regular silica gel column chromatography to yield the desired product 20c. The polarity of this dihydrocaffeic acid derivative 20c is different to that of caffeic acid derivative 16g. Consequently, the difference in polarity resulted in changes in the elution solvent system needed for both TLC and column chromatography. With the same deprotection procedures as was applied for caffeic acid derivative 16g, aqueous KOH and TFA were sequentially used to remove the acetyl and Boc groups, respectively. The TFA salt was subsequently neutralized by aqueous saturated NaHCO₃ to obtain dihydrocaffeic acid derivative 20c with a free primary amino group.
Chapter 4. Results and Discussion

4.1 Synthesis of 3,4-diacetoxycinnamoyl chloride 15a

The attempts to reproduce procedures for acetylation went smoothly without any complications, regardless of the scale of the synthesis (from 0.2 to 5g). The chemical yield of the first several attempts was around 80%, likely due to inadequate control of temperature and rate of addition. Subsequently, the reaction was maintained at -5°C using an ice-salt bath and checking the temperature inside the reaction mixture during the dropwise addition of the acetic anhydride to the mixture, while being mixed with a magnetic stirrer. Owing to these measures, the isolated yield of 15b was increased to 90-96%.

In order to achieve better chlorination to form 15a, it is important to ensure the dryness of the acetylated product, since oxalyl chloride itself can react with water giving off hydrogen chloride (HCl), carbon dioxide (CO₂) and carbon monoxide (CO). As a result, the acetylated product was triturated with hexane and filtered from the mixture to afford 3,4-diacetoxycinnamoyl acid 15b as a colorless powder, and was used immediately for the next reaction without further purification.
For the chlorination step to form 15a, oxalyl chloride was used together with a catalytic amount of DMF. The mechanism of this reaction is illustrated in Scheme 4.1.

![Scheme 4.1. Mechanism of acyl chloride formation with oxalyl chloride.](image)

As above, by-products from this reaction are gaseous (CO, CO₂), which simplifies the purification of the product. Meanwhile, attention should be paid to keep the reaction from getting violent due to the generation of by-products. Thus, oxalyl chloride needs to be added dropwise at a low temperature (-5°C, ice-salt bath with NaCl or CaCl₂) to produce 3,4-diacetoxyccinnamoyl chloride 15a as a pale yellow powder. Toluene was used as a solvent in this reaction. In order to remove the solvent thoroughly (boiling point (Bp) being 111°C), it was necessary to triturate the product with hexane. The yield of 15a was found to be 85%.
4.2 Synthesis of $\text{H}_2\text{N-Orn(Boc)-octyloxyaniline 13a}$

The synthesis of 13a was initially conducted according to previous findings. Before the removal of the Fmoc group from 13d to form 13a, purification of 13d was required. For the initial attempts, both regular silica gel column chromatography and reversed-phase column chromatography were used to separate polar and nonpolar impurities from 13d, based on the procedures described in the literature. The advantage of this technique is that a dependable purity of the product can be achieved via the use of both regular and reversed-phase chromatography. At the end of the purification, a large amount of colorless crystalline precipitate of product appeared in the collected component from the column chromatography. However, despite the good separation obtained with relatively polar impurities, the reversed-phase chromatography using ODS gel was associated with problems, such as slow elution and relatively low yields. The high mesh value (200-400) of ODS may have caused the separation to be so slow that it usually took a few days to collect all of the components. The yield of Fmoc-Orn(Boc)-octyloxyaniline 13d was found to be 53% (after the use of both regular and reversed-phase chromatography).
Scheme 4.2. Preparation of Fmoc-Orn(Boc)-octyloxyaniline 13d with the previously reported method and newly developed technique.

Being aware of the possibility of improvements to the synthetic procedure used, several techniques were tested to remove the polar impurities in this reaction. Eventually, one of the methods was verified to be effective by providing satisfactory separation results in a shorter period of time. In this method, the reversed-phase chromatography was substituted with two washing procedures “II” as shown in Scheme 4.2.

Due to the difference between the product and impurities in their reactivity with NaHCO₃ and their solubility in aqueous solution, the washing procedures were able to separate polar impurities from the
product. In addition, the process only took less than an hour, which makes it much more time-saving than the ODS column chromatography. After the optimization, the yield of Fmoc-Orn(Boc)-octyoxyaniline 13d was increased to 76% (after purification).

Generally, the Fmoc group is susceptible to removal using weak bases, such as piperidine or piperazine. The removal also occurs to be more rapid in a relatively polar medium like DMF, compared to a relatively nonpolar one, such as CH₂Cl₂. The subsequent development of the procedures for the cleavage of Fmoc group has led to milder alternatives, by replacing piperidine with the use of Et₂NH in DMF. Although the polarity of DMF is helpful for deprotection of the Fmoc group, its high Bp (153°C) was an obstacle to obtain a dry product. As a result, DMF, together with the cleavage reagent, were washed out very carefully after Fmoc removal using water to afford the product as a pale yellow solid. The yield for the deprotection step to form product 13a was found to be 87%.

4.3 Synthesis of caffeic acid derivative 16g

Based upon the procedures described in the literature, [207] a few details have been optimized to carry out the coupling reaction in this study. The reaction of 3,4-diacetoxyccinnamoyl chloride 15a with H₂N-
Orn(Boc)-octyloxyaniline 13a, in the presence of DMAP and pyridine in CH₂Cl₂ was conducted under Argon atmosphere.

After the complete consumption of H₂N-Orn(Boc)-octyloxyaniline 13a as monitored by TLC, the reaction mixture was acidified and subjected to extraction with CH₂Cl₂. The concentrated residue, which was a yellow oil, was then purified by silica gel column chromatography. By using gradient elution (hexane-ethyl acetate), the eluent was collected in a series of fractions, so that different compounds can be separated effectively. Along with the increase in the proportions of ethyl acetate to hexane, colorless precipitates started to appear in some of the fractions. TLC was used to identify the compounds that were collected in the different fractions. It turned out that all of the fractions with precipitation contained the same compound, namely the desired product 16a, the Boc-acetyl caffeic acid derivative 16g. The yield of product 16a obtained was determined to be 93%.

To remove the acetyl protecting groups on the phenolic hydroxy groups, aqueous KOH was used and the mechanism for this reaction is shown in Scheme 4.3.

Scheme 4.3. Mechanism for the base-catalyzed hydrolysis of acetoxy group.
As a protecting group, the acetyl group is stable to acid and mild base, but is not compatible with strong nucleophiles. In this study, compound 16a was treated with aqueous KOH solution in a mixture of methanol and tetrahydrofuran (THF) to remove the protecting groups, followed by acidification to form 16d, the mono-Boc protected compound.

In the initial attempts, the reaction mixture was stirred at room temperature for one hour followed by acidification with aqueous HCl. However, the reaction time was found to be too short for the deprotection process to complete. Consequently, after several experiments, the reaction time was extended, so that the reaction mixture was stirred overnight, to afford the complete removal of acetyl groups. The results were verified by IR and LC-MS. The yield of product 16d was 70%.

When it comes to the removal of the Boc group, it could be accomplished by using neat TFA as described in the literature. However, it was found to be difficult, even with sodium hydroxide, to neutralize the excess of TFA to obtain product 16g with free amino group. The removal of the Boc group with neat TFA was compared with using 55% TFA in CH$_2$Cl$_2$, and was found to obtain a better purity of product. Therefore, the procedures for removal of the Boc group in compound 16d were modified to allow the product to be dissolved in a minimum amount of CH$_2$Cl$_2$, followed by addition of TFA. The excess of TFA was then neutralized with aqueous saturated NaHCO$_3$ solution. After
extraction from the aqueous solution, and the organic solution was concentrated to dryness, the yield of caffeic acid derivative 16g was found to be 89%. Due to the high polarity of the product, it could be completely dissolved in a mixture of CDCl₃ and CD₃OD, or CD₃OD alone, for NMR spectroscopy.

4.4 Synthesis of 3,4-diacetoxydihydro-caffeoyl chloride 19b

By using a different starting material, 3,4-dihydroxyhydrocinnamic acid 19, instead of caffeic acid, a novel compound without a double bond beside the carbonyl group was able to be obtained. The difference in structure also resulted in a change in the polarity of the molecule, which further led to changes in some of the experimental phenomena.

For the acetylation of 3,4-dihydroxyhydrocinnamic acid 19, acetic anhydride was added into the reaction mixture at 0°C that was achieved with the use of an ice-salt bath (NaCl) for cooling, and the monitoring inner temperature of the reaction mixture was conducted with a thermometer. After extraction of the reaction mixture with ethyl acetate and THF, the organic solvent was removed by a rotary evaporator, to produce 3,4-diacetoxydihydro-caffeoyl acid 19a. The isolated product 19a was a pale yellow solid. Its yield after drying in a vacuum oven was determined to be 95%.
To prepare the corresponding di-\textit{O}-acetylated dihydrocaffeoyl chloride, compound 19\textit{a} was suspended in toluene with a few drops of DMF. Oxalyl chloride was added dropwise into the reaction mixture. Owing to the generation of gaseous by-products, this reaction should not be performed in a closed system and the temperature should be carefully kept constant at -5°C. The resulting solution was clear and pale yellow when all the materials dissolved and reacted as monitored by TLC. After being concentrated under reduced pressure, a colorless crystalline precipitate appeared in the flask. After drying overnight in the vacuum oven, the yield of product 19\textit{b} was found to be 83%.

4.5 Synthesis of dihydrocaffeic acid derivative 20\textit{c}

The preparation of Boc-acetyl dihydrocaffeic acid derivative 20\textit{a} was carried out by allowing di-\textit{O}-acetylated dihydrocaffeoyl chloride 19\textit{b} generated previously to react with H\textsubscript{2}N-Orn(Boc)-octyloxyaniline 13\textit{a} in CH\textsubscript{2}Cl\textsubscript{2} with DMAP in pyridine under argon atmosphere. After stirring overnight at ambient temperature, aqueous HCl was added into the mixture to remove the remaining reactants (pyridine, DMAP). The acidification turned the mixture cloudy, due to the poor solubility of the product in water. After extraction of the reaction mixture with CH\textsubscript{2}Cl\textsubscript{2} and drying the extract in the usual way with anhydrous Na\textsubscript{2}SO\textsubscript{4} and filtering, the solution turned clear. Then the clear yellow solution was
subjected to rotary evaporation to remove the solvent and afford the residue as light brown oily and viscous crude product.

This residue was dissolved with a minimum amount of CH$_2$Cl$_2$ and was purified by a regular silica gel chromatography using gradient elution (from hexanes to hexanes-ethyl acetate) to afford Boc-acetyl dihydrocaffeic acid derivative $20a$ as a pale brown viscous solid. The yield of compound $20a$ was determined to be 57%, after purification. This yield was not very impressive, which could be due to inadequate reaction time of the coupling step and/or unsatisfactory separation results from the silica column chromatography.

For the removal of the acetyl groups in the compound $20a$, several attempts were made to determine the most favorable reaction time for the deprotection process. With the compound $20a$ dissolved in a mixture of methanol and THF, aqueous KOH solution was still used to restore the hydroxy groups. According to the literature procedure, \cite{207} the reaction mixture was stirred for only one hour at room temperature, which was found to be too short in the present work.

Therefore, in the initial attempt, the reaction mixture of Boc-acetyl dihydrocaffeic acid derivative $20a$ with the base was stirred for two hours at room temperature, followed by acidification with aqueous HCl and extraction with chloroform. However, the resulting yield of $20b$ was only 34%, indicating insufficient time to complete the deprotection.
Consequently, the reaction time was extended to three hours, but the yield was still not good enough as 57%. Eventually, after the addition of aqueous KOH, the mixture was stirred for overnight to ensure adequate time for deprotection. The resulting yield of 20b was found to be improved to 74%. During the experimental development, it was critical to have the correct analytic method to determine the completion of deprotection process. In this case, IR spectroscopy was the most efficient technique to verify the removal of the acetyl groups, which was indicated by the reappearance of an absorption peak of hydroxy groups at ~3330 cm$^{-1}$ (broad, s) in IR spectrum (see A-16 and A-20).

The dihydrocaffeic acid derivative with Boc group 20b was then dissolved in CH$_2$Cl$_2$ and treated with TFA for 1 hour to remove the Boc group. Due to the exothermic nature of this reaction, an ice bath should be applied during the addition of TFA to control the temperature. In order to reduce the consumption of the aqueous NaHCO$_3$ solution to neutralize the excessive TFA, the reaction mixture was directly subjected to rotary evaporation to remove some of the TFA (Bp: 72.4°C). By adding aqueous saturated NaHCO$_3$ solution, the pH of the mixture was changed to 8 as measured with pH test strips.

Owing to the high polarity of the resulting compound, ethyl acetate was used to extract the product from the aqueous phase. After concentration of the solvent to dryness, the yield of dihydrocaffeic acid
derivative 20c was found to be 93%. For the compound’s characterization, CD$_3$OD and methanol were used respectively to dissolve the product for NMR and LC-MS tests.

While the current work has indicated the synthesis of caffeic acid and dihydrocaffeic acid derivatives and their potential as antifungal agents, there are many directions for further development of this work. Further chemical modifications of caffeic acid and dihydrocaffeic acid derivatives may be carried out to achieve better activity and stability. More importantly, proper stability tests should be conducted to determine if the dihydrocaffeic acid derivative has better stability than caffeic acid derivatives. For biological tests, the evaluation of the products should be conducted with both the BDG synthase inhibition assay (with fungal membrane enzyme) and antifungal assay (**in vitro** cell-based).
5.1 Synthesis of 3,4-diacetoxyccinnamoyl chloride 15a

To a solution of caffeic acid 15 (900 mg = 5.00 mmol) and DMAP (15.8 mg = 0.125 mmol) in pyridine (2.5 mL) was added acetic anhydride (1.2 mL = 13 mmol) at 0 °C. The reaction mixture was stirred at room temperature under argon atmosphere overnight. The resultant mixture (clear, almost colorless) was then poured onto crushed ice (turned cloudy right away). The aqueous phase was acidified with aqueous 2.0 M HCl to change the pH to about 2 (even more cloudy). The mixture was extracted with ethyl acetate/THF (3:1; 3 × 30 mL) and organic parts were collected (clear, colorless). The combined extracts were dried over anhydrous Na₂SO₄ and filtered. The solution was then subjected to evaporation on a rotary evaporator (Bp: 50-60 °C) and the residue was triturated with small amount of hexane to afford 3,4-diacetoxyccinnamic acid 15b (1.28 g ≈ 4.84 mmol; 96%) as a colorless powder. This product was used directly for the next reaction without further purification.
The di-O-acetylated caffeic acid 15b was suspended in toluene (25 mL) with 3 drops of DMF (cloudy, milky white). Being kept in an ice-salt bath (NaCl and/or CaCl₂), oxalyl chloride (1.0 mL≈12 mmol) was added dropwise at -5 °C to the mixture. After stirring for 3 h at room temperature, all materials were dissolved resulting in a clear and pale yellow solution. Solvent and unreacted oxalyl chloride were remove with rotary evaporator under reduced pressure (Bp: 70-75 °C). The residual yellowish product was triturated with hexane containing a few drops of ethyl acetate to yield 3,4-diacetoxycinnamoyl chloride 15a as a pale yellow powder (1.16 g≈4.10 mmol; 85%). ¹H NMR (CDCl₃) data (see A-2 for spectrum): δ = 7.72 (d, J = 15.8 Hz, 1H), 7.45 (d, J = 2.1 Hz, 1H), 7.43 (d, J = 2.1 Hz, 1H), 7.25 (d, J = 8.2 Hz, 1H), 6.43 (d, J = 16.0 Hz, 1H), 2.32 (s, 3H), 2.31 (s, 3H). APCI-MS (positive) m/z (see A-1): 284 (M+H), 282, 247, 205, 163.

5.2 Synthesis of H₂N-Orn(Boc)-octyloxyaniline 13a
A mixture of Fmoc-Orn(Boc)-OH 17 (1.82 g≈4.00 mmol), 4-octyloxyaniline (0.890 g≈4.00 mmol), HOBt (0.820 g≈6.00 mmol) and CMC (2.54 g≈6.00 mmol) in 30.0 mL DMF was stirred at room temperature overnight.

**Previous method:**

The resultant mixture was directly chromatographed on a silica gel column. After running the column with hexanes for several times to remove nonpolar impurities (checked by TLC), the column was eluted with chloroform to collect all components remaining. The chloroform eluted part was then re-chromatographed on a ODS column using gradient elution (from water neat to water : methanol = 1:9) to afford Fmoc-Orn(Boc)-octyloxyaniline 13d as a colorless powder (1.42 g≈2.15 mmol, 53.8%).

**Optimized method:**

After stirring overnight, the mixture was diluted with 160 mL ethyl acetate, then washed by water (4 × 40 mL), saturated NaHCO₃ solution (4 × 40 mL), and dried with anhydrous Na₂SO₄. After removal of the solvent under reduced pressure, the residue was purified by silica gel column chromatography (continuous gradient from hexanes : ethyl acetate = 9:1 to ethyl acetate) to yield Fmoc-Orn(Boc)-octyloxyaniline 13d (2.01 g ≈3.05 mmol, 76.3%).
The resulting product $13d$ (2.01 g$\cong$3.05 mmol) was then treated with 3.0 mL Et$_2$NH in 15 mL DMF at ambient temperature for 2 hours. The resultant mixture was diluted with 80 mL ethyl acetate, then washed with water ($6 \times 20$ mL) and dried over anhydrous Na$_2$SO$_4$. After concentration of solvent to dryness, the H$_2$N-Orn(Boc)-octyloxyaniline $13a$ (1.16 g$\cong$2.66 mmol, 87%) was used for further reaction without purification.

5.3 Synthesis of caffeic acid derivative $16g$

To a solution of H$_2$N-Orn(Boc)-octyloxyaniline $13a$ (0.770 g$\cong$1.75 mmol) and DMAP (0.0800 g$\cong$0.650 mmol) in CH$_2$Cl$_2$ (12 mL) and pyridine (4.5 mL), 3,4-diacectoxycinnamoyl chloride $15a$ (1.13 g$\cong$4.00 mmol) was added at room temperature. The reaction mixture (pale yellow solution) was stirred overnight under argon atmosphere. After checking the reaction progress with TLC, the pH value of the reaction mixture was changed to 3 by adding aqueous 1.0 M HCl. The aqueous phase was then extracted with more CH$_2$Cl$_2$ (3-4 times). The combined organic extracts were dried with anhydrous Na$_2$SO$_4$, filtered, and concentrated on a rotary
evaporator (Bp: 35-40°C). The residue was chromatographed on a silica gel column using gradient elution (10-90% ethyl acetate in hexanes) to afford caffeic acid derivative 16a (1.12 g≈1.64 mmol, 93%) as a colorless powder. \(^1\)H NMR (CDCl\(_3\)) data (see A-3 for spectrum): \(\delta = 7.59\) (m, 1H), 7.40 (m, 3H), 7.26 (d, \(J = 1.6\) Hz, 1H), 7.17 (d, \(J = 8.4\) Hz, 1H), 6.83 (d, \(J = 9.0\) Hz, 2H), 6.37 (d, \(J = 15.9\) Hz, 2H), 4.83 (s, 1H), 3.91 (t, \(J = 6.6\) Hz, 2H), 3.49 (m, 1H), 3.15 (m, 1H), 2.31 (m, 2H), 2.29 (s, 3H), 2.28 (s, 3H), 1.59-1.82 (m, 6H), 1.43 (m, 9H), 1.28 (m, 8H), 0.87 (m, 3H), and NH signal. APCI-MS (positive) \(m/z\) (rel. intensity) (A-4): 682 (85), 664(100); APCI-MS (negative) (A-5): 680 (100).

The caffeic acid derivative 16a (0.620 g≈0.900 mmol) was dissolved in THF (2.6 mL) and methanol (2.6 mL). To the mixture was added aqueous-methanolic 0.2 M KOH (water : methanol = 9:1, 3.0 mL). The reaction mixture was stirred overnight at ambient temperature. The mixture was then acidified with aqueous 1.0 M HCl (2.0 mL), followed by extraction with chloroform (3 times). The combined chloroform extracts were dried over anhydrous Na\(_2\)SO\(_4\), filtered, and concentrated to dryness under reduced pressure to yield caffeic acid derivative 16d (0.370g≈0.620 mmol; 70%). \(^1\)H NMR (CD\(_3\)OD) data (see A-6 for spectrum): \(\delta = 7.61\) (s, 1H), 7.55 (d, \(J = 4.8\) Hz, 2H), 7.44 (d, \(J = 4.2\) Hz, 1H), 7.06 (d, \(J = 2.1\) Hz, 1H), 6.92 (s, 2H), 6.81 (d, \(J = 8.2\) Hz, 2H), 6.22 (d, \(J = 15.9\) Hz, 1H), 4.61 (s, 1H), 3.95 (t, \(J = 6.5\) Hz, 2H), 3.38 (m, 1H),
3.13 (m, 1H), 2.32 (m, 2H), 1.94-1.61 (m, 6H), 1.43 (m, 10H), 1.30 (m, 9H), 0.88 (t, J = 6.5 Hz, 3H). APCI-MS (positive) m/z (rel. intensity) (A-7): 598.3 (100, [M+H]+); APCI-MS (negative) (A-8): 596 (100, [M-H]-).

The caffeic acid derivative 16d with Boc group (0.370 g≈0.620 mmol) was dissolved in 15 mL CH₂Cl₂. While stirring with an ice bath, 2.0 mL TFA was added to the solution. The reaction mixture was then stirred at room temperature for 1 hour, followed by removal of unreacted TFA under reduced pressure (Temp: room temperature). To the residue was added 3.0 mL saturated NaHCO₃ solution to change the pH to around 8. The aqueous phase was extracted with ethyl acetate (3 times). The combined organic extracts were concentrated to dryness to obtain caffeic acid derivative 16g (0.270 g≈0.550 mmol; 89%). ¹H NMR (CD₃OD) data (see A-9 for spectrum): δ = 7.42 (d, J = 3.0 Hz, 2H), 7.28 (d, J = 4.6 Hz, 1H), 6.94 (s, 1H), 6.77 (d, J = 8.2 Hz, 2H), 6.68 (s, 1H), 6.30 (d, J = 15.9 Hz, 1H), 4.62 (s, 1H), 3.94 (t, J = 6.4 Hz, 2H), 3.75 (d, J = 1.5Hz, 2H), 2.99 (s, 2H), 1.93 (m, 1H), 1.75 (m, 5H), 1.43 (m, 2H), 1.23-1.37 (m, 8H), 0.89 (t, J = 6.7 Hz, 3H), and some OH and NH signals. APCI-MS (positive) m/z (rel. intensity) (A-10): 498.3 (100, [M+H]+); APCI-MS (negative) (A-11): 496.2 (100, [M-H]-).
5.4 Synthesis of 3,4-diacetoxydihydro-caffeoyl chloride 19b

![19b]

To a solution of 3,4-dihydroxyhydrocinnamic acid 19 (1.82 g ≈ 10.0 mmol) and DMAP (0.0300 g ≈ 0.250 mmol) in pyridine (5.0 mL) was added acetic anhydride (2.4 mL ≈ 25 mmol) dropwise at 0 °C. The reaction mixture was stirred overnight at room temperature under argon atmosphere. The resultant mixture (pale yellow, not clear) was then poured onto crushed ice (turned cloudy quickly). The aqueous phase was acidified with aqueous 2.0 M HCl to change the pH to about 2 (even more cloudy). The mixture was then extracted with ethyl acetate/THF (3:1; 3 × 30 mL) and organic parts were collected (clear, pale yellow). The combined extracts were dried over Na₂SO₄ and filtered. After the removal of the solvent on a rotary evaporator, 3,4-diaceotoxydihydro-caffeoyl acid 19a (2.38 g ≈ 9.51 mmol; 95%) was obtained and immediately used for subsequent reaction.

The 3,4-diaceotoxydihydro-caffeoyl acid 19a (2.38 g ≈ 9.51 mmol) was suspended in toluene (50 mL) with 5 drops of DMF (cloudy, milky white). Being kept in an ice-salt bath (NaCl and/or CaCl₂), oxalyl chloride (1.8 mL ≈ 20 mmol) was added dropwise at -5 °C to the mixture. The reaction mixture was stirred for overnight at room temperature. The
resultant mixture was then subjected to rotary evaporation to remove the solvent and unreacted oxalyl chloride (Bp: 75-80 °C). The product was tritutrated with hexane containing a few drops of ethyl acetate to yield 3,4-diacetoxydihydro-caffeoyl chloride 19b (2.27 g ≈ 7.98 mmol; 83%). $^1$H NMR (CDCl$_3$) data (see A-12 for spectrum): δ = 7.17 (dtd, $J = 7.2, 1.5, 0.7$ Hz, 1H), 7.04 (d, $J = 1.2$ Hz, 1H), 6.96 (t, $J = 1.2$ Hz, 1H), 2.99 (d, $J = 7.4$ Hz, 2H), 2.66 (dd, $J = 4.8, 1.0$ Hz, 2H), 2.28 (t, $J = 1.4$ Hz, 6H).

5.5 Synthesis of dihydrocaffeic acid derivative 20c

![Chemical Structure](image)

To a solution of H$_2$N-Orn(Boc)-octyloxyaniline (1.49 g ≈ 3.42 mmol) and DMAP (0.140 g ≈ 1.13 mmol) in CH$_2$Cl$_2$ (20 mL) and pyridine (8.0 mL), 3,4-diacetoxydihydro-caffeoyl chloride (2.27 g ≈ 7.98 mmol) was added at room temperature. The reaction mixture (dark yellow solution) was stirred overnight under argon atmosphere. The resultant mixture was acidified with aqueous 1.0 M HCl to change the pH to about 3 (more cloudy). The aqueous phase was extracted with more CH$_2$Cl$_2$. The combined organic extracts were dried over anhydrous Na$_2$SO$_4$, filtered,
and concentrated on a rotary evaporator (Bp: 35-40°C). Regular silica gel column chromatography (continuous gradient from hexanes to hexanes : ethyl acetate = 1:9) was carried out to purify the residue and afford dihydrocaffeic acid derivative 20a (1.32 g≈1.93 mmol; 57%). ¹H NMR (CDCl₃) data (see A-13 for spectrum): δ = 7.41 (d, J = 8.8 Hz, 1H), 7.14 (d, J = 1.6 Hz, 1H), 7.10 (d, J = 1.1 Hz, 2H), 7.04 (d, J = 4.2 Hz, 2H), 6.94 (m, 2H), 6.83 (m, 2H), 4.76 (d, J = 29.9 Hz, 2H), 3.92 (t, J = 6.6 Hz, 2H), 3.30 (m, 1H), 3.04 (m, 1H), 2.95 (m, 2H), 2.88 (d, J = 7.2 Hz, 1H), 2.70 (d, J = 4.8 Hz, 1H), 2.28 (s, 6H), 1.79-1.49 (m, 3H), 1.43 (d, J = 4.0 Hz, 9H), 1.16 (m, 8H), 0.87 (t, J = 6.9 Hz, 3H), and NH signals. APCI-MS (positive) m/z (rel. intensity) (A-14): 684 (43, [M+H]), 584 (100); APCI-MS (negative) (A-15): 682 (57, [M+H]), 640 (69), 598 (100).

The dihydrocaffeic acid derivative 20a (0.200 g≈0.290 mmol) was dissolved in 1.0 mL THF and 1.0 mL methanol (clear, yellow solution). Aqueous-methanolic 0.2 M KOH (water : methanol = 9:1, 1.4 mL) was added to the mixture. The reaction mixture was then stirred overnight at room temperature. The resultant mixture was acidified with aqueous 1.0 M HCl (1.0 mL), followed by extraction with chloroform (3 times). The combined chloroform extracts were dried with anhydrous Na₂SO₄ (clear, dark yellow). After filtration and removal of the solvent, dihydrocaffeic acid derivative 20b was obtained as brown solid (0.130 g≈0.220 mmol; 74%). ¹H NMR (CDCl₃) data (see A-17 for spectrum): δ = 7.11-6.77 (m,
1H), 6.73 (dd, J = 9.7, 3.0 Hz, 2H), 6.60 (dd, J = 8.1, 2.0 Hz, 1H), 4.72 (m, 1H), 3.96 (m, 1H), 3.89 (t, J = 6.4 Hz, 1H), 3.26 (m, 1H), 2.94 (m, 2H), 2.82 (t, J = 7.7 Hz, 1H), 2.57 (m, 1H), 1.82-1.64 (m, 3H), 1.43 (m, 9H), 1.35-1.20 (m, 5H), 1.09 (td, J = 7.1, 3.1 Hz, 1H), 0.88 (m, 3H), and NH signals. APCI-MS (positive) m/z (rel. intensity) (A-18): 600 (48, [M+H]+), 610 (100); APCI-MS (negative) (A-19): 598 (100, [M+H]+), 608 (48).

The dihydrocaffeic acid derivative 20b (0.0500 g≈0.0800 mmol) was dissolved in 2.0 mL CH$_2$Cl$_2$. To the solution, 0.3 mL TFA was added in the presence of an ice bath. After stirring at room temperature for 1 hour, the reaction mixture was then subjected to rotary evaporation to remove unreacted TFA and solvent under reduced pressure (Temp: room temperature). To the residue was added 0.3 mL aqueous saturated NaHCO$_3$ solution to change the pH to around 8. The aqueous phase was extracted with ethyl acetate (3 times). The combined organic extracts were concentrated to dryness to afford dihydrocaffeic derivative 20c (0.0400 g≈0.0700 mmol; 88%). $^1$H NMR (CD$_3$OD) data (see A-21 for spectrum): δ = 6.93 (m, 2H), 6.67 (m, 2H), 6.65 (d, J = 1.3 Hz, 1H), 6.53 (d, J = 2.1 Hz, 1H), 6.50 (m, 1H), 3.99 (m, 1H), 3.93 (t, J = 6.4 Hz, 2H), 3.35 (s, 1H), 2.93 (m, 1H), 2.57 (m, 5H), 1.89 (m, 1H), 1.78-1.53 (m, 2H), 1.48-1.26 (m, 10H), 1.23-1.01 (m, 2H), 0.89 (m, 3H) and some OH, NH.
signals. APCI-MS (positive) m/z (rel. intensity) (A-22): 500 (82, [M+H]), 510 (100); APCI-MS (negative) (A-23): 498 (100, [M+H]), 508 (30).
References


[5] **Barron S.** Medical microbiology (4th edition). *University of Texas Medical Branch at Galveston, 1996*


Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents


[38] Metan G., Ağkuş C., Buldu H., Koç A.N. The interaction between piperacillin-tazobactam and assays for Aspergillus galactomannan


[41] **Penack O., Rempf P., Graf B., Thiel E., Blau I.W.** False-positive Aspergillus antigen testing due to application of piperacillin-tazobactam — is it still an issue? *Diagnostic Microbiology and Infectious Disease*, 2008, 60(1): 117-120


Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents


Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents


[58] Del Bono V., Delfino E., Furfaro E., Mikulska M., Nico E., Bruzzi P., Mularoni A., Bassetti M., Viscoli C. Clinical performance of the (1,3)-beta-D-glucan assay in early diagnosis of...
nosocomial Candida bloodstream infections. *Clinical Vaccine Immunology*, 2011, 18(12): 2113-2117


[65] Kourkoumpetis K.T., Fuchs B.B., Coleman J.J., Desalermos A., Mylonakis E. Polymerase chain reaction-based assays for the
Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents.

Clinical Infectious Diseases, 2012, 54(9): 1322-1331


[71] Cuchacovich R. Clinical applications of the polymerase chain
Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents


in solid organ transplant recipients with central nervous system cryptococcosis. *Clinical Infectious Diseases*, **2009**, 49(11): 1721-1728


Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents


Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents


following intravenous-to oral-dose escalation regimens.

*Antimicrobial Agents and Chemotherapy, 2002*, 46(8): 2546-2553


[123] **Schiller D.S., Fung H.B.** Posaconazole: an extended-spectrum
Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents. *Clinical Therapeutics, 2007*, 29(9): 1862-1886


[131] Noxafil (posaconazole) oral suspension *package insert*, Summit, NJ: Schering-Plough, **2006**


of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. *Clinical Infectious Diseases, 2007*, 44(1): 2-12


polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae. *Journal of Infectious Diseases*, **2008**, 198(2): 186-192


with moderate liver disease, and volunteers with renal dysfunction.  
*Journal of Clinical Pharmacology, 2005*, 45(10): 1145-1152


Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents


Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents


Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents

1) S25-S38


[206] Ma C.M., Kully M., Khan J.K., Hattori M., Daneshtalab M.


[208] **Wang W., He X.L., Ma C.M.** Metabolism schemes of chlorogenic, quinic and caffeic acid derivatives in rats deduced by molecular fragments detected with optimized UPLC-APCI-MS/MS conditions. *International Journal of Mass Spectrometry*, 2013, 337: 34-42

Appendices

$^1$H NMR, LC-MS and IR spectra of synthesized compounds:

3,4-diacetoxyacinnamoyl chloride 15a: LC-MS
Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents

3,4-diacetoxy cinnamoyl chloride 15a: $^1$H NMR
Caffeic acid derivative 16a: $^1$H NMR
Caffeic acid derivative 16a: LC-MS (APCI-positive)
Caffeic acid derivative **16a**: LC-MS (APCI-negative)
Caffeic acid derivative 16d: $^1$H NMR
Caffeic acid derivative 16d: LC-MS (APCI-positive)
Caffeic acid derivative 16d: LC-MS (APCI-negative)
Caffeic acid derivative 16g: $^1$H NMR
Caffeic acid derivative 16g: LC-MS (APCI-positive)
Caffeic acid derivative 16g: LC-MS (APCI-negative)
Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents

3,4-diacetoxydihydro-caffeoyl chloride 19b: $^1$H NMR
Dihydrocaffeic acid derivative 20a: $^1$H NMR
Dihydrocaffeic acid derivative 20a: LC-MS (APCI-positive)
Dihydrocaffeic acid derivative 20a: LC-MS (APCI-negative)

<table>
<thead>
<tr>
<th>#</th>
<th>m/z</th>
<th>I</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>180.9</td>
<td>779126</td>
</tr>
<tr>
<td>2</td>
<td>429.1</td>
<td>649657</td>
</tr>
<tr>
<td>3</td>
<td>524.3</td>
<td>4073631</td>
</tr>
<tr>
<td>4</td>
<td>525.3</td>
<td>1368468</td>
</tr>
<tr>
<td>5</td>
<td>566.3</td>
<td>763904</td>
</tr>
<tr>
<td>6</td>
<td>598.3</td>
<td>8187980</td>
</tr>
<tr>
<td>7</td>
<td>599.3</td>
<td>2909301</td>
</tr>
<tr>
<td>8</td>
<td>600.3</td>
<td>679230</td>
</tr>
<tr>
<td>9</td>
<td>607.3</td>
<td>789569</td>
</tr>
<tr>
<td>10</td>
<td>608.3</td>
<td>5499682</td>
</tr>
<tr>
<td>11</td>
<td>609.3</td>
<td>2313110</td>
</tr>
<tr>
<td>12</td>
<td>610.3</td>
<td>642762</td>
</tr>
<tr>
<td>13</td>
<td>624.4</td>
<td>1099777</td>
</tr>
<tr>
<td>14</td>
<td>638.3</td>
<td>1708838</td>
</tr>
<tr>
<td>15</td>
<td>639.3</td>
<td>788626</td>
</tr>
<tr>
<td>16</td>
<td>640.3</td>
<td>597731</td>
</tr>
<tr>
<td>17</td>
<td>641.3</td>
<td>2471050</td>
</tr>
<tr>
<td>18</td>
<td>650.3</td>
<td>2126800</td>
</tr>
<tr>
<td>19</td>
<td>651.3</td>
<td>1226662</td>
</tr>
<tr>
<td>20</td>
<td>665.3</td>
<td>732875</td>
</tr>
<tr>
<td>21</td>
<td>682.3</td>
<td>4705895</td>
</tr>
<tr>
<td>22</td>
<td>683.3</td>
<td>2036034</td>
</tr>
<tr>
<td>23</td>
<td>718.3</td>
<td>1862847</td>
</tr>
<tr>
<td>24</td>
<td>719.3</td>
<td>773649</td>
</tr>
<tr>
<td>25</td>
<td>720.3</td>
<td>885840</td>
</tr>
<tr>
<td>26</td>
<td>804.4</td>
<td>666154</td>
</tr>
<tr>
<td>27</td>
<td>817.4</td>
<td>948649</td>
</tr>
<tr>
<td>28</td>
<td>846.4</td>
<td>1488002</td>
</tr>
<tr>
<td>29</td>
<td>847.4</td>
<td>739220</td>
</tr>
<tr>
<td>30</td>
<td>864.3</td>
<td>642489</td>
</tr>
</tbody>
</table>
Dihydrocaffeic acid derivative **20a**: IR
Dihydrocaffeic acid derivative 20b: $^1$H NMR
Dihydrocaffeic acid derivative 20b: LC-MS (APCI-positive)

<table>
<thead>
<tr>
<th>#</th>
<th>m/z</th>
<th>I</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>238.1</td>
<td>643752</td>
</tr>
<tr>
<td>2</td>
<td>279.1</td>
<td>1633169</td>
</tr>
<tr>
<td>3</td>
<td>317.2</td>
<td>1234999</td>
</tr>
<tr>
<td>4</td>
<td>323.0</td>
<td>473037</td>
</tr>
<tr>
<td>5</td>
<td>379.0</td>
<td>682736</td>
</tr>
<tr>
<td>6</td>
<td>379.1</td>
<td>1260097</td>
</tr>
<tr>
<td>7</td>
<td>380.2</td>
<td>476123</td>
</tr>
<tr>
<td>8</td>
<td>500.3</td>
<td>4840403</td>
</tr>
<tr>
<td>9</td>
<td>501.3</td>
<td>1568910</td>
</tr>
<tr>
<td>10</td>
<td>510.3</td>
<td>1748018</td>
</tr>
<tr>
<td>11</td>
<td>511.3</td>
<td>577233</td>
</tr>
<tr>
<td>12</td>
<td>526.3</td>
<td>1662072</td>
</tr>
<tr>
<td>13</td>
<td>527.3</td>
<td>478617</td>
</tr>
<tr>
<td>14</td>
<td>544.3</td>
<td>3216334</td>
</tr>
<tr>
<td>15</td>
<td>545.3</td>
<td>827842</td>
</tr>
<tr>
<td>16</td>
<td>554.2</td>
<td>1150479</td>
</tr>
<tr>
<td>17</td>
<td>555.3</td>
<td>1059304</td>
</tr>
<tr>
<td>18</td>
<td>582.4</td>
<td>982327</td>
</tr>
<tr>
<td>19</td>
<td>600.3</td>
<td>8430109</td>
</tr>
<tr>
<td>20</td>
<td>601.3</td>
<td>2822414</td>
</tr>
<tr>
<td>21</td>
<td>602.2</td>
<td>721609</td>
</tr>
<tr>
<td>22</td>
<td>610.3</td>
<td>17435040</td>
</tr>
<tr>
<td>23</td>
<td>611.3</td>
<td>6991838</td>
</tr>
<tr>
<td>24</td>
<td>612.3</td>
<td>1802712</td>
</tr>
<tr>
<td>25</td>
<td>655.3</td>
<td>928636</td>
</tr>
<tr>
<td>26</td>
<td>665.3</td>
<td>1591955</td>
</tr>
<tr>
<td>27</td>
<td>666.3</td>
<td>824088</td>
</tr>
<tr>
<td>28</td>
<td>687.3</td>
<td>751796</td>
</tr>
<tr>
<td>29</td>
<td>688.3</td>
<td>524491</td>
</tr>
<tr>
<td>30</td>
<td>818.4</td>
<td>595832</td>
</tr>
</tbody>
</table>
Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents

Dihydrocaffeic acid derivative 20b: LC-MS (APCI-negative)
Synthesis and characterization of caffeic and dihydrocaffeic acid derivatives as antifungal agents

Dihydrocaffeic acid derivative 20b: IR
Dihydrocaffeic acid derivative 20c: $^1$H NMR
Dihydrocaffeic acid derivative **20c**: LC-MS (APCI-positive)
Dihydro-caffeic acid derivative 20c: LC-MS (APCI-negative)